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Key abbreviations  
(in alphabetical order) 
 
A-loop – activation loop 
ABL1 (ABL or c-ABL) – Abelson proto-oncogene 1, non-receptor tyrosine kinase 
ALL – acute lymphoid/lymphoblastic/lymphocytic leukemia 
AML – acute myeloid/myelogenous/myelocytic leukemia 
ATP – adenosine triphosphate  
BCR (c-BCR) – Breakpoint cluster region 
BCR-ABL1 – fusion oncogene composed of BCR and ABL1  
CLL – chronic lymphoid/lymphoblastic/lymphocytic leukemia 
CML (CGL) – chronic myeloid/myelogenous/myelocytic; chronic granulocytic leukemia 
(historical) 
IC50 – half-maximal inhibitory score 
mTOR – mammalian/mechanistic target of rapamycin 
Ph+ – Philadelphia-chromosome positive 
P-loop – ATP-binding domain/pocket/site 
sDSS – selective Drug Sensitivity Score 
SH1-3 – Src homology 
SMAC mimetics – inhibitors that mimic ‘small molecule second mitochondrial activator of 
caspase’ 
TKI – tyrosine kinase inhibitor 
 
Mutation names 
T315I – “gatekeeper” mutation in which threonine is replaced by isoleucine in amino acid position 
315 
T315M – mutation in which threonine is replaced by methionine in amino acid position 315 
E255V/T315I – compound mutation in which glutamic acid is replaced by valine in amino acid 




Given the success of first-line treatment in chronic myeloid leukemia (CML), the prevalence of the 
disease is estimated to increase and more patients are expected to develop resistance to therapy. 
Thus, even relatively rare point mutations are likely to become more common. In CML, the 
uncontrollable division of myeloid cells is caused by a reciprocal translocation of chromosomes 9 
and 22, resulting in the Philadelphia chromosome. At the meeting point of the two chromosomes, 
breakpoint cluster region (BCR) and Abelson proto-oncogene 1 (ABL1) fuse together to form the 
chimeric fusion oncogene BCR-ABL1, the latter of which, the non-receptor tyrosine kinase ABL1, 
is the driver of the disease. Since the tyrosine kinase inhibitor (TKI) imatinib became available in 
2001, the success of first-line therapy has significantly improved the prognosis of CML patients. 
However, up to 50% of patients with imatinib-refractory disease develop resistance due to point 
mutations in ABL1, and the most common mutation to emerge is BCR-ABL1 T315I. The broad-
range TKI ponatinib is the only approved TKI that inhibits the kinase activity of BCR-ABL1 T315I, 
but adverse side effects leave patients with this mutation in need of a better, safer, and more 
effective treatment. The kinase inhibitor axitinib was shown to be selective for BCR-ABL1 T315I, 
but mutations that emerge as a consequence of axitinib-resistance have yet to be explored. 
Moreover, patients with the T315I mutation treated with ponatinib have been reported to develop 
highly drug-resistant mutations in BCR-ABL1 such as T315M and the E255V/T315I compound 
mutation.  
The purpose of this study was to identify mutations that enable cells to develop resistance to the 
kinase inhibitor axitinib and to find new, potential inhibitors for cells expressing the drug-resistant 
mutations BCR-ABL1 T315I, BCR-ABL1 T315M, and BCR-ABL1 E255V/T315I. To this end, 
mouse hematopoietic cell lines were constructed prior to determining cell viability in response to 
inhibitors in combinations and as independent agents. As a novel finding, cells stably expressing 
T315M were found to exhibit sensitivity to inhibitors of topoisomerase II and mTOR. Moreover, 
synthetic lethality occurred in these cells in response to the combined treatment of the allosteric 
inhibitor asciminib and the TKI ponatinib, although not in clinically relevant doses. The highly 
resistant cells expressing BCR-ABL1 E255V/T315I, like cells expressing T315I and T315M, 
showed sensitivity to conventional chemotherapy. Notably, however, three SMAC mimetics 
displayed selectivity to cells expressing BCR-ABL1 E255V/T315I over cells expressing only the 
single T315I mutation.  
Considering that CML is expected to become increasingly prevalent, more patients are estimated to 
develop resistance to therapy. As even relatively rare mutations in BCR-ABL1 become more 
common, finding an effective treatment for cells expressing these highly resistant mutations takes 






1. Literature Review 
 
1.1. Cancer is diverse 
1.1.1. Overview 
If human life expectancy continues to rise as it has done in most countries in the past few decades, 
or even if it plateaus at the current level (Vaupel, 2010), an unprecedented number of people will 
live into old age (Christensen et al., 2009). Even if the population of the world does not surpass ten 
billion people by the end of this century, as predicted by Lutz et al. (2001), the increasing number 
of people, including the elderly, is likely to adjust priorities in the healthcare system.  
With aging, cellular processes in the body become less efficient and mutations in the genome more 
frequent, resulting in a range of age-related diseases (DiLoreto and Murphy, 2015). If a mutation 
affects genes that are responsible for the division and growth of a cell, the cell may become 
incapable of controlling its division and thereby contribute to cancer risk (Stratton et al., 2009). In 
addition to increased age, risk factors for cancer include environmental factors, diet, and individual 
genetic background (Padma, 2015). 
Although advancements in cancer treatments have added valuable years to the lives of cancer 
patients (Siegel et al., 2016), not every patient benefits. Conventional chemotherapy, which has 
focused on finding treatments for large populations, has resulted in reduced rates of metastasis and 
relapse, and increased overall survival (Liu et al., 2015). However, it also often targets all rapidly 
dividing cells and therefore results in frequent side effects (Bagnyukova et al., 2010). In recent 
years, there has been increasing awareness regarding the differences in inherent characteristics 
leading to distinct treatment responses. Indeed, the tremendous complexity and heterogeneity in 
cancer revealed by a plethora of genomic and proteomic data highlights the challenge of finding a 
tailored approach to each individual case (Agyeman and Ofori-Asenso, 2015). Although both are 
considered chemotherapy, conventional chemotherapy does not target cancer cells as specifically as 
targeted therapy (Palumbo et al., 2013). 
 
1.1.2. Targeted therapy 
The purpose of targeted therapy is to design drugs that target specific genes or proteins that single 
out cancer cells or the microenvironment that, among other things, enables the cells to continue to 
divide. The benefit of the targeted approach is explained by increased specificity to the cancer cells 
and the reduction of side effects usually caused by off-target binding of the drug. Targeted therapy 
involves designing compounds that are capable of inciting autophagy or apoptosis, inhibiting the 
division of cancer cells, contributing to cell cycle regulation, and, most importantly, directing toxic 
compounds exclusively to cancer cells to kill them. In particular, the compounds used in targeted 
treatment include small molecule inhibitors and monoclonal antibodies, often in combination with 
chemotherapy or other treatments (Gerber, 2008). Consequently, targeted therapy affects fewer 




1.1.3. Combination therapy 
Combination therapy is another way to increase cancer treatment efficacy. The simultaneous use of 
multiple drugs can prove advantageous for several reasons. First, two or more compounds can 
strengthen a therapeutic effect by increasing efficacy. Second, the use of multiple drugs can result 
in decreased dosages of each drug, which, in turn, can lead to lowered toxicity and fewer side 
effects. Third, successful combination therapy decreases the likelihood of developing drug-
resistance, a frequent challenge and a complex problem to avoid (Chou, 2006; Bukowska et al., 
2015).  
Notably, the interaction between compounds can affect cell growth in different ways. First, 
compounds can act in synergy. Synergy occurs when two or more drugs, when combined, affect 
more cells than the sum of each would predict (1 + 1 > 2). When the potency of combined drugs 
equals to the sum of each, the effect is additive (1 + 1 = 2). However, antagonism occurs when the 
potency of two or more drugs is less than can be predicted from the discrete potency of each drug (1 
+ 1 < 2; Tallarida, 2007; Karjalainen and Repasky, 2016). Among them, synergy provides the most 
therapeutic benefits. In particular, selective synergy offers an efficient clinical tool by selectively 
targeting cancer cells instead of healthy cells (Chou, 2006). Although combinations in cancer 
therapy have not yet been studied and applied as much as clinical demand would suggest, some 
combination therapies have been shown to be clinically effective and many are in clinical trials 
(Karjalainen and Repasky, 2016). 
Combination therapies can include conventional chemotherapy agents, targeted therapy agents, or a 
combination of the two. One example of therapy which combines two targeted compounds is found 
in AML (acute myeloid leukemia). AML is a tremendously heterogeneous leukemia with thousands 
of driver mutations (Papaemmanuil and Gerstung et al., 2016), but the most frequent to occur are 
the FLT3 (FMS-like tyrosine kinase-3) activating mutations. In fact, 30% of AML cases are 
estimated to contain FLT3 mutations (Levis and Small, 2003), making this a desirable drug target. 
Notably, preclinical studies suggest that combining FLT3 inhibitors with inhibitors of HDAC 
(histone deacetylase) leads to synergy between the two compounds (Bali et al., 2004; Pietschmann 
et al., 2012). HDACs have been shown to be involved in activating and regulating nonhistone 
proteins such as HSPs (heat shock proteins). Acetylating Hsp90 renders it inactive and results in 
incorrect folding as well as degradation of its substrate proteins, including FLT3 (Bali et al., 2004). 
Consequently, simultaneous inhibition of HDAC and FLT3 might provide clinical benefits to AML 
patients (Pietschmann et al., 2012). While success does not follow many combinations expected to 
improve the lives of cancer patients, the combinations that lead to favorable outcomes provide an 
opportunity to predict successful combination therapies better. 
 
1.2. Drug-resistance poses a problem  
 1.2.1. Overview 
Drug-resistance in cancer can be divided into two groups: intrinsic (primary) and acquired 
(secondary) (Hayes and Wolf, 1990). In intrinsic drug-resistance, factors contributing to resistance 
are present in the tumor prior to chemotherapy. When drug-resistance is acquired, tumors that 
exhibited initial sensitivity can develop resistance because of emerging mutations or other adaptive 
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means, such as triggering an alternative signaling pathway or increasing the expression of a target 
site (Hayes and Wolf, 1990). Given the enormous heterogeneity in cancer (Swanton, 2012), 
chemotherapy that effectively terminates most of the tumor can induce drug-resistance by selecting 
minor but resistant subpopulations of cancer cells (clonal evolution) (Burrell and Swanton, 2014). 
Furthermore, undifferentiated cells known as cancer stem cells have been implicated in resistance to 
chemotherapy. Both primary and secondary drug-resistance can be caused by inhibition of 
apoptosis, DNA damage repair, epigenetic modifications, or epithelial-mesenchymal transition 
(which enables metastases), as well as drug inactivation, efflux, and target alteration [Figure 1] 
(Housman et al., 2014).  
 
 
Figure 1: Mechanisms that allow or support drug-resistance in cancer are able to act independently or in 
various combinations (adapted from Housman et al., Cancers, 2014) 
 
1.2.2. Drug target alteration 
In order to affect a cancer cell, antineoplastic drugs have to interact with a target. This interaction, if 
successful, leads to a modification or inhibition of the function of the cell. Alterations in the quality 
or quantity of the drug target can weaken drug efficacy (Moscow et al., 2003). Altered drug targets, 
such as changed expression levels, mutations, or signaling pathways, are factors that affect the 
efficacy of a compound. These forms of drug target alterations could eventually result in resistance 
to a compound (Housman et al., 2014). Three of the following examples provide some insight into 
drug target alteration. 
First, while point mutations can cause uncontrolled kinase activity, the overexpression of a gene can 
have a similar effect. For example, 30% of breast cancer patients overexpress HER2 (human 
epidermal growth factor receptor 2), a receptor tyrosine kinase of the EGFR (epidermal growth 
factor receptor) family (Housman et al., 2014). However, resistance to drugs targeting HER2 occurs 
in more than 65% of metastatic breast cancers (Chung et al., 2013). 
Topoisomerase II, an enzyme that precludes the under- or supercoiling of DNA, is targeted by some 
chemotherapy drugs. The complex that forms between topoisomerase II and DNA is typically short-
lived, but topoisomerase II inhibitors stabilize the complex, which results in hindered DNA 
synthesis, DNA damage, and blocked mitotic processes. Although cells achieve resistance by 
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several means, mutations occurring in the topoisomerase II gene have been shown to help cell lines 
confer resistance to drugs targeting topoisomerase II (Housman et al., 2014). 
Chronic myeloid leukemia (CML) provides a good example of drug-target alteration in cancer 
resistance. The malignancy is driven by the uncontrolled activity of the tyrosine kinase in ABL1. 
Inhibitors that are available to treat CML inhibit phosphorylation in the tyrosine kinase domain, but 
point mutations have been shown to emerge in response to inhibitors (Soverini et al., 2011). 
Missense mutations enable BCR-ABL1 to encode a protein altered in size, chemistry and/or shape of 
the target site, often resulting in drug resistance. See Section 1.7.3. for more information. 
 
1.3. Hematopoiesis  
1.3.1. Hematopoietic stem cells 
The process of hematopoiesis takes place in the bone marrow. All blood cells derive from 
pluripotent hemopoietic stem cells, which are capable of renewing themselves and (re-)creating all 
cell lineages. These pluripotent cells, therefore, give rise to myeloid progenitor cells as well as 
lymphoid progenitor cells. Myeloid progenitor cells give rise to red blood cells (erythrocytes), 
platelets, and mast cells, as well as eosinophils, basophils, neutrophils, and macrophages. Lymphoid 
progenitor cells give rise to natural killer cells (NK cells), B-lymphocytes (also known as B-cells) 
and T-lymphocytes (also known as T-cells) [Figure 2] (Essential Haematology, 2011).  
 
 
Figure 2: All blood components are created in the process of hematopoiesis. The pluripotent hematopoietic 
stem cell can give rise to myeloid progenitors and lymphoid progenitors, each of which, in healthy individuals, 




1.3.2. Abnormal hematopoiesis can result in leukemia 
If an aberration prevents the normal development of white blood cells in the bone marrow, 
leukemia can occur (Enciso et al., 2015). Leukemia is a cancer of the blood characterized by 
abnormal hematopoiesis in the bone marrow and elevated numbers of white blood cells that have 
not fully matured. Leukemias can be divided in two groups: acute and chronic leukemias, with each 
further divided into myeloid and lymphoid malignancies (Essential Haematology, 2011). The four 
leukemias are estimated to make up 85% of all leukemias [Figure 3] (Cook and Pardee, 2013). 
Acute leukemias often have an aggressive, fast onset, while chronic leukemias progress more 
slowly (Essential Haematology, 2011). It is important to note that these four leukemias can be 
further subdivided into many categories and do not include all forms of hematologic malignancies 
(Essential Haematology, 2011; Taylor et al., 2017).  
 
 
Figure 3: Hierarchy of leukemias: Four of the most common subtypes of leukemias (according to Cook and 
Pardee, Cancer Metastasis Rev., 2013). Leukemias can be divided into acute and chronic leukemias, each of 
which is subdivided into myeloid and lymphoid malignancies. The numbers for incidence and 5-year survival are 
according to the statistics of the SEER program (Surveillance, Epidemiology, and End Results Program, National 
Cancer Institute; 1975-2014). Incidence is described as the number of new cases per year. AML – acute myeloid 
leukemia; ALL – acute lymphoid leukemia; CML – chronic myeloid leukemia; CLL – chronic lymphoid leukemia  
 
1.4. Chronic Myeloid Leukemia (CML) 
1.4.1. Overview 
Chronic myeloid leukemia (CML), also known as chronic myelogenous, myelocytic, or 
granulocytic leukemia (CGL), is a slowly progressing cancer of white blood cells characterized by 
an uncontrolled production of immature myeloid cells. The worldwide incidence of leukemia is 
estimated to be 2,5% of all cancers (Ferlay et al., 2015), and the relatively rare CML constitutes 
around 15% of leukemias (Essential Haematology, 2011) with an annual incidence rate of 
approximately 1-2 per 100 000 people worldwide (Dikshit et al., 2011). The malignancy is slightly 
more common in males with a male to female ratio of 1,4:1 (Essential Haematology, 2011), and 
incidence increases with age. The median age at diagnosis is estimated to be 64 years (SEER 
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program, 2017). Since the introduction of the tyrosine kinase inhibitor (TKI) imatinib in 2001 
(Druker et al., 2001), successful first-line therapy for CML has decreased the estimated annular 
mortality of CML from 10-20% prior to the use of imatinib down to 1-2% since introducing the 
kinase inhibitor (Jabbour and Kantarjian, 2016). In spite of the unchanging incidence of CML, the 
prevalence of the disease is expected to increase more than six-fold by year 2050 (Huang et al., 
2012) because CML patients who would have died prior to the use of TKIs can now expect to live 
almost as long as healthy individuals (Bower et al., 2016) [Figure 4].  
 
 
Figure 4: The number of patients living with CML has been increasing since the tyrosine kinase inhibitor 
(TKI) imatinib was introduced in 2001, and is predicted to reach a plateau only by the year 2050. The 
number of CML cases is estimated to rise more than six-fold when compared to the era prior to imatinib (used and 
modified with permission from Huang et al., Cancer, 2012) 
As the cancer progresses, three sequential phases can be distinguished: an initial chronic phase 
(which is the most common time of diagnosis), an accelerated phase, and an aggressive blast crisis 
phase (Jabbour and Kantarjian, 2016). Blast crisis occurs when the bone marrow and/or blood 
contains more than 20% of immature white blood cells (or extramedullary proliferation of blasts 
can be detected) (Shi et al., 2015). Blast lineage is myeloid in around 70% of CML cases and 
lymphoid in 20-30% of cases (Derderian et al., 1993; Nair et al., 1995). 
 
1.4.2. Fusion oncogene BCR-ABL1  
CML is characterized by the presence of the Philadelphia (Ph) chromosome, which was the first 
chromosomal aberration connected to a human malignancy (Dobrovic et al., 1991). The Ph-
chromosome results from the reciprocal translocation of the long arms of chromosomes 9 and 22, 
and forms a shortened chromosome 22 (Nowell and Hungerford, 1960; Rowley, 1973) referred to 
as t(9;22)(q34;q11) (Prakash and Yunis, 1984) [Figure 5 and 6c]. At their meeting point, the 
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chimeric oncogene BCR-ABL1 is formed when breakpoint cluster region (BCR) gene from 
chromosome 22 fuses with Abelson proto-oncogene 1 (non-receptor tyrosine kinase; ABL) from 
chromosome 9 (de Klein et al., 1982; Heisterkamp et al., 1983a; Groffen et al., 1984; Shtivelman et 
al., 1985). The resulting uncontrolled tyrosine kinase activity in the ABL1 protein is also the driver 
of the malignancy (Lugo et al., 1990; Deininger et al., 2000a).  
 
 
Figure 5: Reciprocal translocation of the long arms of chromosomes 9 and 22 leads to the so-called 
Philadelphia chromosome, where BCR (chromosome 22) fuses with ABL1 (chromosome 9), forming the 
fusion oncogene BCR-ABL1. The resulting constitutively active tyrosine kinase domain in ABL1 is responsible 
for the oncogenic transformation. 
The difference in breakpoints in the BCR gene can lead to the expression of proteins of different 
molecular masses, namely 185/190 kDa (p190BCR-ABL1), 210 kDa (p210BCR-ABL1), and 230 kDa 
(p230BCR-ABL1), all with constitutively activated tyrosine kinase activity. The three resulting fusion 
proteins comprise the same sequence of the ABL1 gene at the C-terminus but contain a different 
amount of BCR at the N-terminus (Li et al., 1999). Since over 95% of CML patients carry the 
p210BCR-ABL1 oncogenic fusion protein (Melo, 1997), descriptions of the structure of BCR-ABL1 in 
this thesis will focus on the p210BCR-ABL1 form of BCR-ABL1 (referred to as BCR-ABL1 in this 
thesis). 
 
1.4.3. BCR (Breakpoint Cluster Region) 
The BCR gene is evolutionarily conserved and ubiquitously expressed (Collins et al., 1987). 
Although the function of the BCR gene encoding protein in a healthy individual is largely unclear, 
BCR has been shown to code for a 160 kD protein with serine/threonine kinase (Maru and Witte, 
1991) and guanosine triphosphase activities (Diekmann et al., 1991). At the N-terminus of the BCR 
protein, a coiled-coil oligomerization motif is thought to be pivotal to the constitutive activation of 
the ABL1 tyrosine kinase in BCR-ABL1 [Figure 6a] (McWhirter et al., 1993). The role of other 
BCR domains in the malignant process may be limited and include the serine/threonine SH2-




1.4.4. ABL1 (Abelson Proto-oncogene 1) 
The ABL1 gene (also c-ABL1), ubiquitously expressed in humans (Wang, 2014), is homologous to 
the v-abl oncogene (Heisterkamp et al., 1983b) found in A-MuLV (Abelson murine leukemia virus) 
(Reddy et al., 1983). It encodes a 145 kD protein that, among other functions, is involved in a 
variety of processes related to cell growth and survival, motility and adhesion, apoptosis, and 
reaction to DNA damage (Deininger et al., 2000b; Wang, 2014). 
The ABL1 protein occurs in two isoforms (1a and 1b) resulting from alternative splicing of the first 
exon (Deininger et al., 2000b). Many structural regions can be delineated [Figure 6b]. Specifically, 
three regions homologous to Src (SH1-SH3) are found close to the N-terminus. Most importantly, 
the SH1 domain contains the non-receptor tyrosine kinase domain that is constitutively activated in 
BCR-ABL1 (Salesse and Verfaillie, 2002). Proline-rich domains are found at the center of ABL1 
(Yu et al., 1994) and nuclear localization signals (NLS) are interspersed with proline-rich regions 
(van Etten et al., 1989). DNA binding and F-actin-binding domains (Kipreos and Wang, 1992; 
McWhirter and Wang, 1993), as well as a nuclear export signal (NES) (Taagepera et al., 1998), are 
located toward the C-terminal end of the ABL1 protein (Deininger et al., 2000b). 
In ABL, the structures thought to be significant to the oncogenic transformation of BCR-ABL1 are 
the SH2 domain (Src Homology 2), acting-binding domain, and, most important to the work 
presented here, the tyrosine kinase domain. The tyrosine kinase domain in ABL1 is responsible for 
the uncontrolled kinase activity in BCR-ABL1 (Salesse and Verfaillie, 2002). Mutational analyses 
have shown that tyrosine kinase activity is crucial for oncogenic transformation of BCR-ABL, and 
no downstream effector is able to complement it (Lugo et al., 1990; Cortez et al., 1995). The 
tyrosine kinase domain in ABL1 is also the target of TKIs currently available to treat CML (Mughal 




Figure 6: The BCR (p160), ABL1 (p145), and BCR-ABL1 proteins (p210). Key structural domains are 
indicated. (a) At the N-terminus, BCR contains a coiled-coil oligomerization region reported to activate the 
tyrosine kinase in ABL1. (b) ABL1 includes an SH1 non-receptor tyrosine kinase domain, which becomes 
constitutively activated in BCR-ABL1. (c) The p210BCR-ABL1 protein isoform contains the indicated regions of 
BCR located toward the N-terminus, and all the ABL1 regions except for the SH3 domain toward the N-terminus.  
SH2 BD – Src Homology 2 binding; Y177 – tyrosine residue at position 177; SH3 – Src Homology 3; SH2 – Src 
Homology 2; NLS – nuclear localization signals; DNA BD – DNA binding; actin BD – actin binding  
(adapted from Smith et al., Expert Rev. Mol. Med., 2003, and Salesse and Verfaille, Oncogene, 2002) 
 
1.4.5. 3D structure of ABL1 kinase domain 
The crystal structure of the ABL1 kinase domain facilitates an understanding of drug targeting 
[Figure 7]. In particular, the ABL1 kinase domain consists of the smaller N-lobe or N-terminal lobe, 
which is located above the ATP-binding pocket, and the larger C-lobe or C-terminal lobe, situated 
below the ATP-binding pocket (Reddy and Aggarwal, 2012). The ATP-binding pocket of ABL1 is 
the location that, in BCR-ABL1, enables incessant phosphorylation (Mughal et al., 2013). The 
ATP-binding pocket (also known as P-loop) is flexible and covers the bound ATP molecule (Reddy 
and Aggarwal, 2012). For this reason, TKIs that bind to the P-loop are known as ATP-competitive 
inhibitors of ABL1. Consequently, by preventing phosphorylation, the growth of cells expressing 
BCR-ABL1 is restricted, or the cells die by apoptosis (Mughal et al., 2013). Mutations that affect 
the binding of an inhibitor to the ATP site may cause drug-resistance. For example, a threonine 
residue (Thr315) just outside of the P-loop is referred to as the “gatekeeper” (Reddy and Aggarwal, 
2012), and is often replaced by isoleucine (T315I) in imatinib-refractory CML patients (Gorre et al., 
2001).  
The myristoyl binding site is located toward the C-terminus of the ABL1 kinase domain. It is the 
allosteric site of ABL1, and inhibitors targeting this pocket have been shown to affect the structural 
dynamics of the ATP-binding pocket. This effect has been exemplified by the allosteric inhibitors 
GNF-2 and GNF-5 (Novartis Pharmaceuticals). Specifically, a moderate synergy has been shown 
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between the allosteric inhibitor GNF-5 and the ATP-competitive inhibitors nilotinib (Tasigna; 
Novartis Pharmaceuticals) or dasatinib (Sprycel; Bristol-Myers Squibb) when inducing loss of 
viability in cells expressing T315I. As single agents, none of these compounds shows efficacy 
toward cells expressing T315I (Zhang et al., 2010; Iacob et al., 2011). This finding highlights the 
potential of combination treatment to induce loss of cell viability in drug-resistant cells when both 
the ATP-binding site and the allosteric site (myristate pocket) are targeted.  
 
 
Figure 7: Crystal structure of ABL1 kinase domain. Highlighted are the ATP-binding pocket or P-loop (pink) 
and myristate pocket or allosteric site (blue). The amino acid residue E255 (glutamic acid at position 255) and 
T315 (threonine at position 315) are shown in yellow and will be elaborated on in Section 1.7.3 (picture used and 
modified with permission; Gambacorti-Passerini et al., The Lancet Oncology, 2003) 
 
 
1.5. History of treating CML 
Before the first tyrosine kinase inhibitor (TKI) imatinib became available for treating CML in 2001 
(Druker et al., 2001), CML was treated with non-specific chemotherapy agents such as the 
alkylating agent busulfan and the antimetabolite hydroxyurea, as well as the human cytokine 
interferon-α (INF-α) and allogeneic stem cell transplantation (Silver et al., 1999). In the 1980s, 
INF-α became the first-line treatment for CML patients in chronic phase who failed to clinically 
qualify for allogeneic bone marrow transplantation (Kujawski et al., 2007). However, response to 
INF-α varied from successful inhibition of the leukemic clone to no ‘hematologic’ effect (Dowding 
et al., 1993), and side effects and eligibility problems limited the use of the aforementioned 




1.6. TKIs (tyrosine kinase inhibitors) 
1.6.1. First-generation TKIs 
The first tyrosine kinase inhibitors, referred to as tyrphostins (inhibitors of tyrosine 
phosphorylation), were reported in 1988 by Yaish et al. Through the process of random, high-
throughput screening, 2-phenylaminopyrimidine was identified as a TKI that showed selectivity for 
the PDGFR (platelet-derived growth factor receptor) and ABL1 tyrosine kinases (Buchdunger et 
al., 1996; Carroll et al., 1997; Druker and Lydon, 2000). To optimize the compound for increased 
specificity and potency for PDGFR inhibition (its initial target), various compounds chemically 
related to 2-phenylaminopyrimidine were synthesized by analyzing the association between activity 
and structure (Druker and Lydon, 2000). STI-571 (CGP57148B, imatinib mesylate) surfaced as a 
promising compound for preclinical studies not only for inhibiting PDGFR but Kit and ABL1 
tyrosine kinases as well (Buchdunger et al., 1996; Druker et al., 1996). STI-571 was found to bind 
and stabilize the ATP-binding domain (P-loop) in the catalytic region of ABL1 so that the kinase 
stays in an inactive state. Thus, the conformation of the P-loop is misshapen and the A-loop stays in 
a closed DFG (Asp-Phe-Gly)-out conformation (Schindler et al., 2000). A few years after STI-571 
was found to inhibit the ABL1 tyrosine kinase, preclinical research was followed by clinical trials. 
In 1998, Phase I clinical trials were initiated using STI-571 for treating CML patients ineligible for 
INF-α treatment. When STI-571 was given in (daily) doses of 300mg or higher, 98% of CML 
patients achieved a complete hematologic response, and the response usually occurred within the 
first month (Druker et al., 2001). The United States Food and Drug Administration (FDA) approved 
imatinib mesylate (Gleevec or Glivec; Novartis Pharmaceuticals) in 2001 (Cohen et al., 2002). Five 
years later, the overall survival of CML patients receiving imatinib as first-line treatment was 
assessed to be over 85% (Druker et al., 2006). For CML patients in chronic phase, the estimated 
eight-year survival rate has advanced from 20% historically to over 85% since imatinib became 
available. CML patients diagnosed in accelerated phase have an estimated 75% eight-year survival, 
but blast phase CML patients face a dismal median survival of seven months (Kantarjian et al., 
2012). 
Even though long-term complete cytogenetic response is achieved in most Ph+ leukemia patients, 
treatment is discontinued in many due to occurrence of resistance or intolerance (Branford et al., 
2002). In addition to the inefficacy of imatinib in treating advanced CML (Kantarjian et al., 2012), 
imatinib-treatment can result in the selection of point mutations in the tyrosine kinase domain of 
BCR-ABL1 (Soverini et al., 2011), which can lead to resistance to imatinib even at increased doses 
(Wieczorek and Uharek, 2015). 
 
1.6.2. Second- and third-generation TKIs 
Crystallography facilitated the synthesis of second-generation TKIs, such as nilotinib (Tasigna; 
Novartis Pharmaceuticals), dasatinib (Sprycel; Bristol-Myers Squibb) and bosutinib (Bosulif; 
Pfizer). The second-generation TKIs were found to exhibit selectivity for the BCR-ABL1 mutations 
not affected by imatinib (Shah et al., 2004; Weisberg et al., 2006). However, none of these three 
TKIs could suppress the BCR-ABL1 T315I mutation that emerges in up to 20% of refractory 
patients (Nicolini et al., 2009). Although the third-generation TKI ponatinib (Iclusig; ARIAD 
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Pharmaceuticals) inhibits this mutation, additional mutations have emerged and many of them defy 
inhibition even by this broad-target TKI (Lasater et al., 2016).  
Table 1 summarizes information on TKIs currently available for CML treatment.  
 
Table 1: Information on FDA approved TKIs currently available for CML treatment. The first column 
indicates the generation of the TKI. 
 
 
1.7. Drug-resistance in CML 
1.7.1. Overview 
Drug-resistance in CML can be primary or secondary. Primary drug-resistance in CML consists of 
two types of resistance. One of them is primary cytogenetic resistance (15-25% of cases), which 
occurs when the patient has no change in the number of Philadelphia-chromosome positive (Ph+) 
cells in the bone marrow within 12 months. The second is primary hematologic resistance (2-4% of 
patients), when complete blood count, peripheral blood smear, or the size of the spleen do not return 
to normal within three months (Haznedaroglu, 2014; Jabbour et al., 2011). Point mutations in BCR-
ABL1 are seldom behind primary drug-resistance (Jabbour et al., 2011). The mechanisms 
associated with primary resistance include aberrant expression of a drug transporter or deficient 
protein binding. Secondary resistance occurs in patients who achieved cytogenetic and/or 
hematologic response initially but later developed resistance (lost response), usually due to a 
mutation in the ABL1 tyrosine kinase domain. Drug-resistance to TKIs can occur either through 
BCR-ABL1-independent or BCR-ABL1-dependent mechanisms (Bhamidipati et al., 2013; 
Wieczorek and Uharek, 2015). 
 
1.7.2. Mechanisms of BCR-ABL1-independent resistance  
BCR-ABL1-independent mechanisms of resistance to TKIs often, but not always, occur as primary 
resistance, and include aberrations in drug influx, import, binding and concentration, as well as 
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activation of an alternative signaling pathway and epigenetic modifications (Bixby and Talpaz, 
2009). For example, mechanisms independent of BCR-ABL1 include:   
• elevated drug efflux due to higher expression of P-glycoprotein efflux pumps (Rumpold et 
al., 2005); 
• abnormal drug transporter expression, including hOCT1 (human organic cation transporter 
1) that affects imatinib-resistance (Thomas et al., 2004); 
• multidrug resistance ATP-binding cassette (ABC) transporters ABCB1 or MDR1 and 
ABCG2 shown to influence resistance to imatinib, nilotinib, and dasatinib (Dohse et al., 
2010); 
• serum protein α1 acid glycoprotein binding to imatinib, prevents drug-mediated inhibition of 
BCR-ABL1 (Gambacorti-Passerini et al., 2000); 
• the metabolism gene PTGS1/COX1 (prostaglandin-endoperoxide synthase 1/ 
cyclooxygenase 1), which codes for an imatinib-metabolizing enzyme, and thus increased 
transcript levels of the gene have been linked to BCR-ABL1-independent mechanisms of 
resistance (Zhang et al., 2009). 
 
1.7.3. Mechanisms of BCR-ABL1-dependent resistance  
BCR-ABL1-dependent mechanisms of resistance include overexpression or amplification of the 
BCR-ABL1 gene or its encoded protein (le Coutre et al., 2000), and point mutations that emerge in 
the ABL1 tyrosine kinase domain (Gorre et al., 2001). Mechanisms dependent on BCR-ABL1 are 
more frequent, especially point mutations. In fact, point mutations are estimated to arise in up to 
50% of CML cases that become resistant to imatinib due to impaired binding. Studies have found 
over 90 point mutations resulting in amino acid substitutions in the tyrosine kinase domain of BCR-
ABL1, including the domain that binds ATP (P-loop), the activation loop (A-loop), the catalytic 
motif, and amino acids which come in contact with imatinib (Jabbour et al., 2011).  
The frequency of a certain point mutation, as well as its effect on the sensitivity of the cell to TKIs, 
varies (Jabbour et al., 2011). Most of the amino acid substitutions found to be clinically relevant 
emerge at residues in the  
• P-loop (Y253F/H, E255V/K, G250E, and M244V at the periphery of the P-loop),  
• catalytic domain (F359V, M351T), and 
• contact site (T315I) (Soverini et al., 2006).  
Substitutions at these seven residues make up 85% of all mutations linked to resistance [Figure 8] 
(Soverini et al., 2006), with T315I alone accounting for up to 20% of resistance to first and second 
generation TKIs (Nicolini et al., 2009). Mutations in the P-loop have been associated with shorter 
survival and a quicker transformation to blast crisis (Branford et al., 2003), but these findings are 
contradictory (Jabbour et al., 2006). More than one point mutation can occur in a single patient, and 
this happens more often when the patient has been treated with more than one TKI (Jabbour et al., 
2011). Highly resistant compound mutations have also been shown to emerge (Zabriskie et al., 
2014). The abundance of point mutations that occur in response to kinase inhibitors highlights the 




Figure 8: The BCR-ABL1 tyrosine kinase domain and the seven amino acid substitutions within it that 
make up 85% of mutations linked to resistance. Key structural domains in tyrosine kinase domain are shown. 
P-loop refers to ATP-binding loop; SH2 and SH3 contact domains indicate locations of contact with proteins that 
contain SH2 and SH3 domains; A-loop indicates activation loop. Amino acid substitutions relevant to this thesis 




The first identified point mutation emerging in the tyrosine kinase domain of BCR-ABL1 was a 
nucleotide change of C to T (ACT -> ATT) that leads to the substitution of the hydrophilic, polar 
threonine (T) with the nonpolar isoleucine (I) at the amino acid position 315 in the ABL1 tyrosine 
kinase domain (Gorre et al., 2001) [Figure 9]. Threonine at position 315 (Thr315) forms a crucial 
hydrogen bond with the TKI imatinib, but because its side chain usually provides the oxygen atom 
that is missing in isoleucine, the secondary amino group of imatinib can no longer bind hydrogen. 
However, isoleucine does not prevent ATP binding (Gorre et al., 2001). Even though many point 
mutations have been described, T315I has remained the most significant. Importantly, this T315I 
mutation is referred to as the “gatekeeper” mutation because of its location in the periphery of the 
nucleotide-binding site (Nagar et al., 2002), and tyrosine kinase activity of BCR-ABL1 with the 
T315I mutation cannot be inhibited by any of the first or second generation TKIs (Wehrle et al., 
2014). 




Figure 9: In T315I, threonine (T) in amino acid position 315 is replaced by isoleucine (I) because of the 
emergence of a missense mutation when the nucleotide C is replaced by T. 
The T315I mutation in imatinib-refractory CML occurs between 2-20% of cases, with inconsistency 
associated with differences in patient cohort size, treatment, and mutation detection methods 
(Nicolini et al., 2009). Ph+ ALL (acute lymphoid leukemia) patients appear to carry the T315I 
mutation more frequently, and those affected face a dire overall survival of only five months. The 
frequency of the T315I mutation in CML probably increases as TKI treatment is sustained (Soverini 
et al., 2006 and 2007; Nicolini et al., 2009).  
In 2009, the presence of the gatekeeper mutation T315I was correlated with a 22-month overall 
survival in chronic phase CML patients (Nicolini et al., 2009). The third-generation TKI ponatinib 
(Iclusig, ARIAD Pharmaceuticals) was designed to bind to the inactive conformation of ABL1 and, 
especially, ABL1T315I. Unlike imatinib, ponatinib does not bind hydrogen with the side chain of 
Thr315 in ABL1 protein. The significant structural characteristic of ponatinib is the triple bond 
between two carbons, which leads to successful hydrophobic contact with the side chain of Ile315 
and enables the thus-far cross-resistant T315I to be inhibited (O’Hare et al., 2009).  
In 2012, the FDA gave accelerated approval to ponatinib for treating Ph+ ALL or CML adult 
patients ineligible for prior TKI treatment (Bose et al., 2013). However, the drug was withdrawn 
from the market a year later due to concerns of serious side effects, including thrombotic vascular 
events (Sanford et al., 2015). A phase II study was carried out to determine the effects of ponatinib 
as first-line treatment for chronic phase CML, but it was terminated because of elevated risk of 
thromboembolism (Jain et al., 2015). In 2014, ponatinib was again approved for CML patients 
carrying the T315I mutation, or when other TKIs are not indicated (Sanford et al., 2015), but side 
effects continue to be a concern (Poch Martell et al., 2016).  
Notably, our group determined that the kinase inhibitor axitinib is a potential alternative to 
ponatinib (Pemovska et al., 2015). Axitinib exhibited a high affinity for T315I in kinase assays 
(Davis et al., 2011), and showed clinical activity in a CML patient with the T315I mutation 
(Pemovska et al., 2015), making axitinib, previously approved by the FDA for advanced renal cell 
carcinoma, a desirable inhibitor for drug-repurposing (Tyler, 2012). Although concerns over 
adverse events have led to suggestions of decreased dosages for ponatinib, efficacy and safety may 
be complex to balance, and ponatinib may be incompatible in advanced cases of CML (Dorer et al., 
2016). Given that nearly a hundred point mutations have been shown to arise as a result of treating 
CML with TKIs (Soverini et al., 2011), it is reasonable to conclude that point mutations would also 
arise in the ABL1 kinase domain of axitinib-treated patients. Yet, mutations occurring as a result of 
axitinib-treatment have yet to be explored. 
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BCR-ABL1 T315M  
BCR-ABL1 T315M (hereafter referred to as T315M), although rare, presents a case of a mutation 
in which the amino acid encoded by a codon changes from hydrophilic, polar threonine (T) to 
hydrophobic, non-polar methionine (M), with the added step of two nucleotide exchanges (ACT -> 
ATT -> ATG) [Figure 10]. This change has been shown to occur when the gatekeeper mutation 
T315I is treated with ponatinib and develops resistance to the drug (Zabriskie et al., 2014). In fact, 
cells stably expressing the mutation have displayed a high degree of resistance to ponatinib (Lasater 
et al., 2016). No compound thus far has been shown to selectively inhibit the T315M mutation. 
 
 
Figure 10: The T315M mutation appears to involve the amino acid substitution threonine (T) to methionine 
(M) at position 315, but two nucleotide exchanges are needed for this to occur. 
 
BCR-ABL1 E255V/T315I 
Unlike T315M, BCR-ABL1 E255V/T315I is a compound mutation that involves two separate 
nucleotide exchanges at distinct amino acid positions. T315I, as explained previously, refers to the 
substitution of threonine for isoleucine at position 315. In E255V, however, the polar glutamic acid 
is replaced by the nonpolar valine at amino acid position 255. Both positions are frequent sites for 
single mutations, and when they occur together as E255V/T315I [Figure 11], this compound 
mutation is the most frequent to emerge at 17% of compound mutations (Zabriskie et al., 2014).  





Figure 11: In E255V/T315I compound mutation, glutamic acid (E) is replaced by valine (V) at amino acid 
position 255, and threonine (T) replaced by isoleucine (I) at position 315. 
Although ponatinib has shown the most extensive activity of all the ABL1-specific TKIs (Lasater et 
al., 2016), the compound mutation E255V/T315I, like T315M, arises as a result of ponatinib-
treatment and therefore confers resistance to the drug (Zabriskie et al., 2014). No drug has so far 
been shown to selectively target E255V/T315I in clinically relevant quantities.  
Due to the success of imatinib and the subsequent second-generation TKIs, the prevalence of CML 
is increasing worldwide (Huang et al., 2012), making even the rare point mutations necessary drug-
targets. The increasing prevalence of CML underlies the need for effective and selective inhibitors 
of drug-resistant mutations.  
 
1.8. Summary  
CML is a myeloproliferative malignancy defined by the fusion oncogene BCR-ABL1, which leads 
to uncontrolled kinase activity of the tyrosine kinase domain of ABL1. The introduction of the 
tyrosine kinase inhibitor (TKI) imatinib as first-line treatment for CML has rapidly improved the 
prognosis of the disease. However, point mutations in ABL1 account for up to 50% of acquired 
resistance, and T315I is the most frequent mutation to arise. The only approved TKI showing 
efficacy toward this mutation is ponatinib, which has severe side effects. Although axitinib has 
previously shown selectivity for cells expressing the T315I mutation, mutations emerging as a 
consequence of axitinib-therapy have yet to be examined. Furthermore, new and highly resistant 
mutations such as T315M and E255V/T315I have been reported in CML patients who previously 
carried the T315I mutation and were treated with ponatinib. Thus far, no compound has shown 
selective potency to cells expressing the two highly resistant mutations in clinically relevant 





1.9. Aims of this study 
 
1. To identify new potential inhibitors for a mouse hematopoietic cell model stably expressing 
the BCR-ABL1 T315I, T315M and E255V/T315I mutations. 
 






2. Experimental Research  
 
2.1. Identifying new potential inhibitors for cells expressing the BCR-ABL1 
T315I, T315M, and E255V/T315I mutations 
 
2.1.1. Rationale 
The prognosis for CML patients improved tremendously after successful introduction of the first 
TKI imatinib in 2001 (Druker et al., 2001 and 2006). However, in spite of the prolonged lifespan of 
many CML patients and availability of second- and third-generation inhibitors, drug-resistance 
continues to be a problem (Zabriskie et al., 2014). Treating CML and Ph+ ALL patients with 
ABL1-specific TKIs often results in the emergence of point mutations in the tyrosine kinase domain 
of ABL1 (Gorre et al., 2001). One of the most frequent mutations to occur is T315I, which has been 
estimated to make up to 20% of the mutations arising from drug resistance (Nicolini et al., 2009). 
The broad-range TKI ponatinib is available to treat patients with this mutation (Bose et al., 2013). 
However, as a result of treatment with ponatinib, the T315M and the compound mutation 
E255V/T315I have been found to emerge. Although rare, these two mutations have been shown to 
be resistant to all approved ABL-1 specific TKIs (Lasater et al., 2016; Zabriskie et al., 2014). 
Considering the estimated increasing prevalence of CML in the world for the next three decades 
(Huang et al., 2012), even the now-rare mutations are likely to pose a problem in the future. Thus, a 




Reliable testing of small-molecule kinase inhibitors requires a cellular assay system dependent on 
kinase activity. For this purpose, the murine interleukin-3 (IL-3)-dependent pro-B cell line Ba/F3 
was used. This model system is non-leukemic and dependent on the cytokine IL-3 in the absence of 
an oncogene but becomes independent of IL-3 after transformation by an oncogene (Gesbert et al., 
2000). The Ba/F3 cell model has been shown to be an efficient and effective model for testing the 
ability of kinase inhibitors to hinder kinase activity (Warmuth et al., 2007). 
Ba/F3 parental cells were maintained in growth medium consisting of RPMI 1640 (Lonza; 
#11675180/BE12-167F), 10% FBS (fetal bovine serum; Thermo Fisher Scientific; #16000044), 
penicillin-streptomycin at 100 units/ml (Thermo Fisher Scientific; #15140-122), 2 mM L-glutamine 
(Thermo Fisher Scientific; #25030-024), and 10 ng/ml of mouse IL-3 (interleukin-3) recombinant 
protein (eBioscience; #14-8031-62). Ba/F3 cells stably expressing BCR-ABL1 were kindly 
provided by Tea Pemovska. Ba/F3 cells stably expressing T315I, T315M or E255V/T315I, 
respectively, were maintained in growth medium containing RPMI 1640, 10% FBS, penicillin-
streptomycin at 100 units/ml, and 2 mM L-glutamine. To avoid undesired surface adhesion, all 
Ba/F3 cell lines were maintained at subconfluence in non-tissue culture treated petri dishes (BD 




The virus packaging cell line 90.74, referred to as CRL-11654 (derived from Human Embryonic 
Kidney cell line HEK293; ATCC), was maintained in growth medium consisting of DMEM 
(Dulbecco’s Modified Eagle Medium); 10% FBS, and penicillin-streptomycin at 100 units/ml. The 
CRL-11654 cells were maintained at subconfluency in tissue culture treated T-75 flasks 
(Corning/Labnet; #430641U) and Tryple Express Enzyme (Thermo Fisher Scientific; #12605-028) 
was used to detach CRL-11654 cells from the flask. CRL-11654 cells used in the following 
experiments did not exceed 25 passages. 
All cell lines were maintained in at 5% CO2 (carbon dioxide) in a humidified incubator at 37 °C.  
 
2.1.3. Methods  
2.1.3.1. Ba/F3 cells stably expressing BCR-ABL1 T315I, T315M or E255V/T315I 
Transfection of a virus-packaging cell line CRL-11654 
A lipid-mediated transfection was used to produce replication-incompetent retroviruses.  Three 
plasmids contained the respective coding sequences for pMIG-BCR-ABL1 T315I, pMIG-BCR-
ABL1 E255V/T315I, and pMIG-BCR-ABL1 T315M. Next, the plasmids were packaged by the 
virus-packaging cell line CRL-11654. The presence of specific coding sequences within the 
plasmids was confirmed by capillary sequencing.  
The cells were transfected using Lipofectamine 2000 Transfection Reagent according to the 
protocol by Invitrogen (#11668-019). On day 5 (72 h post-transfection), the growth medium 
containing retroviruses with the respective pMIG-BCR-ABL1 T315I, pMIG-BCR-ABL1 
E255V/T315I, or pMIG-BCR-ABL1 T315M plasmids was collected with 5 ml syringes (VWR 
International; #613-5401) and filtered through Whatman Puradisc 0.45 µm filters (Sigma-Aldrich; 
#Z612510).  
 
Ba/F3 cell infection  
On day 5, Ba/F3 parental cells in non-tissue culture treated 6-well plates (Thermo Fisher Scientific; 
#351146) were infected with undiluted retroviruses that incorporated pMIG-BCR-ABL1 T315I, 
pMIG-BCR-ABL1 E255V/T315I, and pMIG-BCR-ABL1 T315M. Hexadimethrine bromide 
(Sigma-Aldrich; #H9268) was used to boost gene transfer effectiveness in retroviruses (Davis et al., 
2002) at a final concentration of 4 µg/ml. Growth medium was replaced on day 6 to Ba/F3 growth 
medium described above, containing 10 ng/ml of IL-3. On day 7, Ba/F3 growth medium was 
replaced with growth medium lacking IL-3 to select for cells stably expressing the desired plasmids. 
The growth medium was changed every 2-3 days. Since the presence of an oncogene, such as BCR-
ABL1 T315I, BCR-ABL1 T315M, or BCR-ABL1 E255V/T315I ensures the ability of Ba/F3 cells 
to grow in the absence of IL-3 (Gesbert et al., 2000), removing the cytokine from growth medium 
allowed for selection of a stably expressing population of cells. The selection was complete when 




2.1.3.2. Testing the sensitivity of cell lines to inhibitors    
1. Overview 
The sensitivity of cell lines to compounds described in the following sections were all tested in 
tissue culture-treated microplates in 384-well format (Corning; #3712). Unless stated otherwise, all 
plates were prepared and supplied by Laura Turunen (High Throughput Biomedicine Unit, FIMM). 
Wells containing dimethyl sulfoxide (DMSO) served as the negative control, and benzoyl chloride 
(BzCl) as the positive control. Exceptions will be stated in relevant sections. 
In all three-day cell viability assays, cell viability was determined using CellTiter-Glo 2.0, which 
produces luminescence in response to ATP released from ruptured cells and thereby indicates 
metabolically active cells (Promega). To determine sensitivity of model cell lines to tested 
compounds, half-maximal inhibitory concentrations or IC50s (concentration of a given drug that 
induces loss of cell viability in 50% of the cells) were calculated. Notably, the absolute 
concentration of compound capable of compromising cell viability in 50% of cells is not necessarily 
comparable between inhibitors. Ba/F3 cells are considered sensitive to a drug, e.g. ponatinib, at IC50 
< 25 nM whereas the same cell line is considered be sensitive to imatinib at IC50 < 1000 nM 
(Zabriskie et al., 2014). 
 
2. Sensitivity of cell lines to selected inhibitors 
To determine the effect of selected kinase inhibitors on Ba/F3 cells stably expressing BCR-ABL1, 
T315I, E255V/T315I, or T315M, cells stably expressing the respective mutations were treated with 
nine-point semi-logarithmic scale concentrations of 12 inhibitors [Figure 12]. The chosen 
concentration range for any inhibitor was either 0,1-1000 nM or 1-10 000 nM. 
 
 
Figure 12: 384-well plate layout containing the 12 selected compounds (plate layout by Tea Pemovska was 
modified by the author). Plate layout contained the kinase inhibitors (1) danusertib, (2) nilotinib, (3) saracatinib, 
(4) imatinib, (5) AT9283, (6) bosutinib, (7) ponatinib, (8) dasatinib, (9) axitinib, (10) rebastinib, (11) bafetinib, 
and (12) GNF-2. Dimethyl sulfoxide (DMSO) served as the negative control, and benzoyl chloride (BzCl) as the 
positive control.  
5000 cells/well or 200 cells/µl were calculated using the Scepter 2.0 Cell Counter (Merck 
Millipore). 25 µl/well was dispensed in a 384-well format. The plates were incubated for 72 h in a 
 
 27 
humidified incubator containing 5% CO2 at 37 °C. Cell-Titer Glo 2.0 (Promega; #G9243) reagent 
was added at 25 µl/well at room temperature. The cells were incubated in the dark for ten minutes 
at room temperature. Cell viability was determined using CellTiter-Glo 2.0. To measure 
luminescence, PHERAstar FS microplate reader (BMG Labtech) was used, and the results were 
analyzed with GraphPad Prism 7 (GraphPad Software). The experiment was repeated three times.  
 
3. High-throughput screening  
High-throughput screening was performed on Ba/F3 cells stably expressing the respective 
oncogenes BCR-ABL1, T315I, T315M, or E255V/T315I. To observe the effect of inhibitors on 
non-transformed cells, Ba/F3 parental cells were included. The cells were treated with two sets of 
compounds. One, a collection of over 500 investigational and approved compounds in more than 50 
drug classes in the FIMM oncology drug set (FO4B). Two, the cells were treated with >350 
compounds in the Published Kinase Inhibitor Set (PKIS) by GlaxoSmithKline (GSK; Drewry et al., 
2014). Cells stably expressing BCR-ABL1 were treated with compounds in the FO4B but not PKIS. 
Inhibitors in both drugs sets contained a five-point logarithmic concentration of each drug.  
Cell and Cell-Titer Glo 2.0 reagent dispensing was automated. Multidrop Combi nL Reagent 
Dispenser (Thermo Fisher Scientific) was used to measure 5 µl of growth medium in each well. 
Next, 20 µl of 5000 cells/well was dispensed using MultiFlo FX microplate dispenser (BioTek). 72 
h later, MultiFlo FX microplate dispenser was used to distribute 25 µl of CellTiter-Glo 2.0 on the 
cells. Incubation, luminescence measuring, and analysis occurred as described in Section 2.1.3.2-2.  
The programming necessary to analyze the results of PKIS screening was kindly done by Aleksandr 
Ianevski. In addition, the in-house developed software Breeze was used to analyze results and 
calculate drug sensitivity scores (DSS). DSS is an algorithmic approach for quantitative drug 
sensitivity scoring that provides the means to identify drug-sensitive (cancer) cell lines and cancer-
selective drugs (Yadav et al., 2014). For a better comparison, the DSS’s for cells stably expressing 
the four respective oncogenes were subtracted from the corresponding DSS for Ba/F3 parental cells, 
which provided the so-called ‘selective DSS’ (sDSS) value. Compounds with sDSS > 5 are 
considered to be selective and sDSS > 10 are considered to be highly selective (Pietarinen et al., 
2015). Although arbitrary, this score helps to understand which drugs act selectively toward a 
particular cell line when compared to the other cell lines. 
 
 
4. Sensitivity of cells expressing BCR-ABL1 T315M to inhibitors of mTOR, topoisomerase II, 
and other pathways 
To refute the possibility that the effect of specific inhibitor groups on cells expressing T315M was 
population-specific, a new population of T315M-expressing cells was made using the protocol 
described in Section 2.1.3.1. 36 compounds from the FO4B drug set were chosen based on their 
potency and sDSS toward cells stably expressing T315M when compared to parental cells. Nine-
point semi-logarithmic concentrations of the inhibitors were put on six 384-well plates according to 
the modified plate layout created by Tea Pemovska [Figure 12]. The selected compounds included 
inhibitors of  
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• mTOR,  
• topoisomerase II,  
• mitosis,  
• aurora pathway,  
• farnesyltransferase, 
• Plk1 (polo-like kinase 1; serine/threonine protein kinase), 
• VEGFR (vascular endothelial growth factor receptor), 
• KSP/Eg5 (kinesin spindle protein / kinesin-5), 
• poly-ADP-ribose polymerase, 
• tyrosine kinase,  
as well as IAP SMAC mimetics (mimics of ‘small molecule second mitochondrial activator of 
caspase’ that target inhibitors of apoptosis proteins), an anti-metabolite, a platinum-based 
antineoplastic agent, and an ATP-noncompetitive inhibitor that was not included in the FO4B drug 
set. Chosen drug concentration ranges included 0,1-1000 nM, 1-10 000 nM, 2,5-25 000 nM, or 10-
100 000 nM of inhibitor. 
The cell viability assay was carried out according to the protocol in Section 2.1.3.2.-3. Ba/F3 
parental cells were used as the control group. Data was analyzed and IC50 values calculated using 
GraphPad Prism 7 and DSS values were kindly calculated by Swapnil Potdar.  
 
5. Sensitivity of cells expressing BCR-ABL1 E255V/T315I to selected inhibitors 
To test the sensitivity of cells stably expressing E255V/T315I to seven selected inhibitors, a 
viability assay was performed as described in Section 2.1.3.2.-2. Three IAP SMAC mimetics and 
two Hsp90 (Heat shock protein 90) inhibitors were chosen based on their potency toward cells 
expressing E255V/T315I. The allosteric inhibitor asciminib (ABL-001; currently developed by 
Novartis Pharmaceuticals) and the broad-range TKI ponatinib added up to a total of seven 
inhibitors. The drug plates were made manually. The selected compounds were dispensed in nine-
point semi-logarithmic scale concentrations. As previously, growth medium containing DMSO 
equivalent to the volume of the highest concentration of compound served as the negative control, 
but this assay had no positive control. Cells stably expressing BCR-ABL1 were chosen as control 
group, and the experiment was carried out in duplicates. Concentration ranges of inhibitors 
contained 0,1-1000, 1-10 000 or 2,5-25 000 nM of drug. 
 
6. Combination testing 
To determine if the viability of cells stably expressing E255V/T315I or T315M, respectively, could 
be compromised by targeting different sites of the ABL1 kinase domain, combination testing was 
performed. The kinase inhibitors axitinib and ponatinib, and IAP SMAC mimetic LCL-161 were all 
respectively combined with asciminib [Figure 13]. Cells stably expressing BCR-ABL1 were chosen 
as control group to cells carrying the respective oncogenes.  
A viability assay was carried out according to the protocol described in Section 2.1.3.2.-3., and the 
in-house developed software Breeze SynergyFinder (Ianevski et al., 2017) was used to plot data and 
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calculate synergy according to the ZIP (Zero Interaction Potency) method. The ZIP method enables 
comparison between compounds, separately and in combinations, by comparing the potency 
differences of the dose-response curves (Yadav et al., 2015). For more information on synergy, see 
Section 1.1.3. and 1.4.5. 
 
 
Figure 13: A 384-well plate layout for combination testing of the kinase inhibitors axitinib and ponatinib, 
and the IAP SMAC mimetic LCL-161, in combination with the ATP-noncompetitive inhibitor asciminib 
(ABL-001). The plate is divided into six sections (three replicates), with the concentration of drugs arising in a 
semi-logarithmic manner from left to right and from top to bottom in each section. DMSO served as the negative 






Drug-resistance in the form of point mutations has been shown to occur when CML patients are 
treated with tyrosine kinase inhibitors. In particular, cells carrying T315M and E255V/T315I in the 
ABL1 tyrosine kinase domain display high resistance to all ABL1-specific TKIs (Zabriskie et al., 
2014). Although the broad-range TKI ponatinib shows potency against the “gatekeeper mutation” 
T315I, taking this compound can lead to worrying adverse effects (Jain et al., 2015). To address 
this problem, mouse hematopoietic cell models were constructed. Notably, these cell lines have 
been shown to be useful in observing the effects of kinase inhibitors on kinase activity (Warmuth et 
al., 2007). Furthermore, to find new potential compounds that show selective potency toward these 
mutations, sensitivity of cells expressing the respective mutations was tested to single compounds 
and combinations of them in three-day cell viability assays with Cell-Titer Glo in 384-well format. 
 
2.1.4.1. Cells expressing BCR-ABL1 T315M showed resistance to ABL1-specific kinase 
inhibitors 
Considering that no approved ABL1-specific tyrosine kinase inhibitor had shown selective potency 
toward cells stably expressing T315M (Lasater et al., 2016), a mouse hematopoietic cell line 
expressing T315M was constructed. Next, these cells were treated with 12 selected inhibitors to 
determine if previously published results were reproducible as well as to find potential 
investigational drugs capable of compromising cell viability in T315M-expressing cells. A cell 
viability assay was carried out prior to data analysis with GraphPad Prism to determine half-
maximal inhibitory concentrations (IC50s).  
Ba/F3 cells stably expressing T315M showed moderate or high resistance to the tested compounds 
[Figure 14]. The broad-range TKI ponatinib, although moderately resistant, showed most potency 
toward cells stably expressing T315M (IC50 = 76 nM). The cells exhibited resistance toward 
axitinib (IC50 = 390 nM). The kinase inhibitors danusertib, saracatinib, imatinib, and bosutinib 
compromised cell viability of T315M-expressing cells only in extremely high concentrations [IC50 
> 1000 nM for all four inhibitors]. Moreover, T315M-expressing cells showed complete resistance 
to the ATP-noncompetitive inhibitor GNF-2 (IC50 > 10 000 nM).  
The compounds included in the experiment but not mentioned here (nilotinib, AT9283, dasatinib, 
rebastinib, bafetinib) were excluded on the premise of not meeting the constraint criteria used in 
GraphPad Prism 7 because no tested amount of compound managed to induce loss of cell viability 





Figure 14: Cells stably expressing T315M showed moderate or high resistance to tested ABL1-specific 
kinase inhibitors. Data is representative of three respective experiments. 
In conclusion, cells stably expressing T315M displayed moderate or high resistance to all approved 
and investigational TKIs as well as the allosteric inhibitor GNF-2. This result suggests that, in order 
to selectively compromise cell viability of T315M-expressing cells, the ABL1 kinase domain might 
have to be targeted at several sites. Another possibility is that compounds which target other 
pathways in the cell might show selective potency toward these cells.  
 
2.1.4.2. Novel finding: Cells expressing BCR-ABL1 T315M exhibited selective sensitivity to 
inhibitors of mTOR and topoisomerase II 
Considering that no tyrosine kinase inhibitor (TKI) displayed selective potency toward cells 
expressing T315M, a high-throughput screening was performed to find new potential inhibitors for 
these cells. In this process, cells expressing T315M were treated with over 800 compounds in the 
FIMM oncology collection (FO4B) and the Published Kinase Inhibitor Set (PKIS; GSK). A cell 
viability assay was performed prior to calculating IC50s and selective Drug Sensitivity Scores 
(sDSS) with the software Breeze. 
As a novel finding, cells stably expressing T315M exhibited selective sensitivity to various 
inhibitors of mTOR and topoisomerase II. After calculating the sDSS for all compounds in the two 
drug sets for the four cell lines expressing the respective oncogenes, a pattern of sensitivity emerged 
for cells expressing T315M. The selectivity of mTOR and topoisomerase II inhibitors to cells 
expressing T315M was only comparable to cells expressing BCR-ABL1, which was unusual [data 
not shown]. Among others, mTOR pathway inhibitors ridaforolimus (IC50 = 1 nM), everolimus 
(IC50 = 1 nM), temsirolimus (IC50 = 1 nM), AZD8055 (IC50 = 77 nM), and MLN-0128 (IC50 = 39 
nM) showed selective sensitivity toward cells expressing T315M [Table 2]. The cells showed 
sensitivity toward several topoisomerase II inhibitors, including mitoxantrone (IC50 = 34 nM), 
amsacrine (IC50 = 21 nM), teniposide (IC50 = 24 nM), doxorubixin (IC50 = 32 nM) and 
aldoxorubicin (IC50 = 19 nM). Cells stably expressing T315M showed sensitivity to inhibitors of 
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various other pathways, including but not limited to inhibitors of topoisomerase I [data not shown], 




Table 2: Cells stably expressing T315M revealed a pattern of sensitivity to several mTOR and 
topoisomerase II inhibitors, as well as drugs targeting other pathways. Customized plates for cells stably 
expressing the T315M mutation (“Custom”) were made after several topoisomerase II and mTOR inhibitors 
compromised cell viability in the cell line. Results in the columns labelled “FO4B” show the results of one high-
throughput screening and columns labelled “Custom” represent an average of duplicates. 
	 FO4B	 Custom	 FO4B	 Custom	 	 FO4B	 Custom	 FO4B	 Custom	
	 Compound	 IC50	(nM)	 sDSS	 Compound	 IC50	(nM)	 sDSS	
mTOR	inhibitors	 	 	 	 Aurora	inhibitors	 	 	
1.	 dactolisib	 26	 14	 5,4	 12,9	 23.	 alisertib	 198	 53	 10,5	 5,8	
2.	 MLN-0128	 39	 35	 6,4	 13,1	 24.	 tozasertib	 829*	 41*	 6	 4,3	
3.	 vistusertib	 502	 321	 4,1	 11,1	 25.	 GSK-1070916	 31	 17	 5,2	 1,8	
4.	 AZD8055	 77	 60	 9,5	 11,9	 KSP/Eg5	inhibitor	
5.	 NVP-BGT226	 18	 9	 6,8	 9,4	 26.	 filanesib	 4	 6	 12,9	 5,5	
6.	 gedatolisib	 54	 28	 3,3	 10,1	 Mitotic	inhibitors	
7.	 everolimus	 1	 7	 16,4	 7,3	 27.	 paclitaxel	 5	 2	 12	 8,5	
8.	 temsirolimus	 1	 0,7	 16,4	 15,2	 28.	 docetaxel	 4	 1	 11,9	 4,7	
Farnesyltransferase	inhibitors	 29.	 vinorelbine	 6	 5	 16,6*	 0,2*	
9.	 lonafarnib	 713	 373	 4,3	 4,6	 30.	 ABT-751	 411	 281	 6,2	 3,3	
10.	 tipifarnib	 30	 26	 12,8	 18,2	 31.	 cabazitaxel	 2	 1	 14	 17,2	
Plk1	inhibitors	 Platinum-based	antineoplastic	agent	
11.	 GSK-461364	 129	 41	 7,2	 3,1	 32.	 cisplatin	 824	 1096	 10,3	 6	
12.	 BI	2536	 51	 26	 7,3	 6	 Poly-ADP-ribose	polymerase	inhibitor	
Topoisomerase	II	inhibitors	 33.	 talazoparib	 68	 60	 7,8	 5,7	
13.	 idarubicin	 6	 3	 5,4	 3,3	 Anti-metabolite	
14.	 etoposide	 222	 53	 7,7	 3,3	 34.	 gemcitabine	 33	 18	 7,2	 5,8	
15.	 teniposide	 24*	 5637*	 8,3*	 0,1*	 ATP-noncompetitive	inhibitor	
16.	 doxorubicin	 32	 15	 6	 4,4	 35.	 asciminib	 –	 >1000	 –	 0	
17.	 aldoxorubicin	 19	 13	 8	 3,7	 Broad-range	TKI	(control)	
18.	 mitoxantrone	 34*	 0,7*	 8,5	 5,1	 36.	 ponatinib	 27	 112	 16,8	 11,2	
19.	 amsacrine	 21	 10	 8,5	 4,1	 	 	 	 117	 	 10,9	
IAP	SMAC	mimetics	 	 	 	 116	 	 10,9	
20.	 AT-406	 456	 232	 5,5	 15,5	 VEGFR	inhibitor	
21.	 birinapant	 93	 94	 5,1	 9,3	 37.	 axitinib	 258	 277	 16,7	 3,1	
22.	 LCL-161	 168	 88	 9,5	 22,3	 	 	 	 	 	 	
IC50 – half-maximal inhibitory concentration; nM – nanomoles; sDSS – selective Drug Sensitivity Score; Plk1 – polo-like 
kinase 1 (serine/threonine-protein kinase); IAPs – inhibitor of apoptosis proteins; SMAC mimetic – inhibitors that mimic 
‘small molecule second mitochondrial activator of caspase’ (SMAC); KSP/Eg5 – kinesin spindle protein / kinesin-5; ADP – 
adenosine diphosphate; ATP – adenosine triphosphate; TKI – tyrosine kinase inhibitor; VEGFR – vascular endothelial growth 
factor receptor 
* Result pairs with an absolute fold-change that is equal to or more than 20 have been indicated with asterisks. 
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To ensure that the selective sensitivity of cells carrying T315M to inhibitors of mTOR and 
topoisomerase II was not population-specific, a new population of Ba/F3 cells stably expressing 
T315M was made and tested to 36 inhibitors selected from the high-throughput screening. In 
addition, the allosteric inhibitor asciminib was added to the customized plates. 
Results of the second screening supported the first finding: the new population of cells carrying 
T315M also displayed sensitivity toward inhibitors of mTOR and topoisomerase II. The cells 
showed selective sensitivity toward mTOR inhibitors such as everolimus (IC50 = 7 nM), 
temsirolimus (IC50 = 1 nM), AZD8055 (IC50 = 60 nM), MLN-0128 (IC50 = 35 nM), and others. 
Topoisomerase II inhibitors, such as mitoxantrone (IC50 = 1 nM), amsacrine (IC50 = 10 nM), 
doxorubicin (IC50 = 15 nM) and aldoxorubicin (IC50 = 13 nM) showed selective potency toward 
cells expressing T315M. Unlike the results for the FO4B drug screening, the new population of 
T315M-expressing cells appeared to display resistance to the topoisomerase II inhibitor teniposide 
(IC50 > 5000 nM). However, considering the high chemical similarity between teniposide and 
etoposide, it is possible that this last result is an error in dispensing the drug. 
In addition to inhibitors of mTOR and topoisomerase II, the new population of cells expressing 
T315M was sensitive to compounds that target other pathways, such as the farnesyltransferase 
inhibitor tipifarnib (IC50 = 26 nM), the Plk1 inhibitor BI 2536 (IC50 = 26 nM), and the SMAC 
mimetic LCL-161 (IC50 = 88 nM), among others.  
Although both experiments revealed that inhibitors of mTOR and topoisomerase II showed 
selective potency toward T315M-expressing cells when compared to cells expressing T315I or 
E255V/T315I, a slight variation in results was observed. When all compounds in Table 2 are 
considered except for the five results with an absolute fold-change ≥ 20, the average absolute fold-
change in IC50 values is 2,4, and the average absolute fold-change in sDSS values is 1,9. The fact 
that topoisomerase II and mTOR inhibitors continue to show selectivity to T315M-expressing cells 
even when this heterogeneity is taken into account further supports the strength of this finding. 
Although toxicity concerns may limit the clinical value of this selectivity, the result raises questions 
about using inhibitors of mTOR or topoisomerase II in combination with other compounds.  
 
2.1.4.3. Combination testing resulted in unprecedented synthetic lethality in cells expressing 
BCR-ABL1 T315M 
To investigate possible synergy between ATP-competitive and ATP-noncompetitive inhibitors, 
combination testing in cells stably expressing T315M was performed. Cells expressing BCR-ABL1 
served as control. The ATP-competitive kinase inhibitors ponatinib and axitinib were tested in 
combination with the allosteric inhibitor asciminib. In addition, the SMAC mimetic LCL-161, 
which gave promising results as an independent compound in cells expressing T315M (IC50 = 115 
nM), was combined with asciminib. Data was analyzed with the ZIP (Zero Interaction Potency) 
method using the software SynergyFinder.  
The TKIs ponatinib and axitinib, when combined with the allosteric inhibitor asciminib, had a high 
synergistic growth inhibitory effect on cells stably expressing T315M. A strong synthetic lethality 
was observed (ZIP synergy score = 36,5) on cells stably expressing T315M cells when the allosteric 
inhibitor asciminib was combined with the broad-range TKI ponatinib [Figure 15 and 16]. 
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Combining asciminib and the kinase inhibitor axitinib on cells stably expressing T315M 
demonstrated synergy (ZIP synergy score 11.7) centering on 100-300 nM of axitinib and 100-3000 
nM of asciminib [data not shown]. However, combining the SMAC mimetic LCL-161 with the 
ATP-noncompetitive compound asciminib resulted in antagonism (ZIP synergy score -4.4) in cells 
stably expressing T315M [data not shown]. 
 
 
Figure 15: Combinatorial treatment of the tyrosine kinase inhibitor ponatinib and the allosteric inhibitor 
asciminib revealed strong synergy in high concentrations of both compounds in cells stably expressing 
T315M. (a) Synergy heatmap of ponatinib and asciminib in T315M-expressing cells. Red area indicates synergy, 
whereas green indicates antagonism. The white area surrounded by red signifies synergy >100%, which is 
possible when an individual drug acts antagonistically (% inhibition < 0) but the combination of two drugs in the 
same concentration is lethal to the cells; (b) Dose-response matrix of the combination treatment. Data are shown 





Figure 16: Dose-response landscape of the synthetic lethality between the tyrosine kinase inhibitor 
ponatinib and the ATP-noncompetitive inhibitor asciminib in cells stably expressing T315M. The results are 
representative of duplicates. 
Although the combination of the TKI ponatinib and the allosteric inhibitor asciminib resulted in 
unusually high ZIP synergy scores, clinical relevance of the finding is doubtful because the 
concentrations of asciminib and ponatinib are much too high to prevent toxicity. However, the 
strength of this synergy suggests that combinations of other TKIs and ATP-noncompetitive drugs 
may exist which compromise cell viability in T315M-expressing cells at much lower 
concentrations. Moreover, if computer design of each compound were to be a viable option, 
modifications to the compounds may also lead to synergy at lower concentrations of drugs. 
Interestingly, this ZIP synergy score is so high as to enable consideration of the combination of 
asciminib and ponatinib in T315M-expressing cells as the positive control for combination testing.  
 
2.1.4.4. Cells expressing BCR-ABL1 E255V/T315I displayed complete resistance to all 
approved TKIs 
Given that patients with E255V/T315I mutations have been shown to display high resistance to all 
available tyrosine kinase inhibitors (Zabriskie et al., 2014), cells stably expressing E255V/T315I 
were constructed. Then, a viability assay was carried out on the cells to find if E255V/T315I-
expressing cells show sensitivity to any approved and investigational ABL-1 specific TKIs. Finally, 
to assess the sensitivity of cells to selected inhibitors, half-maximal inhibitory concentrations were 
calculated with GraphPad Prism. 
Cells stably expressing E255V/T315I exhibited complete resistance to all 12 selected inhibitors. 
Although IC50 values could be achieved or calculated for eight compounds (danusertib, saracatinib, 
imatinib, bosutinib, ponatinib, axitinib, bafetinib, and GNF-2), none of the inhibitors showed 
potency toward cells stably expressing E255V/T315I (IC50 > 1000 nM for all; IC50 > 10 000 nM for 
saracatinib, imatinib, and GNF-2) [Figure 17]. Nilotinib, AT9283, dasatinib, and rebastinib failed to 




Figure 17: Cells stably expressing E255V/T315I exhibited complete resistance to all tested tyrosine kinase 
inhibitors, and one allosteric inhibitor. Note that when compared to cells stably expressing T315M, the dose-
response curves have shifted to the right on the x-axis because a higher concentration of inhibitors is needed to 
compromise cell viability in E255V/T315I-expressing cells. Data are representative of three individual 
experiments. 
To summarize, it appears that two separate amino acid substitutions in E255V/T315I-expressing 
cells could be responsible for the extremely high resistance of these cells to all selected inhibitors. 
Cells expressing E255V/T315I compare unfavorably to T315M-expressing cells, which needed 
lower concentrations of drugs to achieve IC50s. The resistance of these cells to all selected inhibitors 
does, however, highlight the necessity of high-throughput screening with E255V/T315I-expressing 
cells. 
 
2.1.4.5. IAP SMAC mimetics show selective potency to BCR-ABL1 E255V/T315I-expressing 
cells when compared to T315I-expressing cells 
Considering that cells stably expressing E255V/T315I showed complete resistance to ABL1-
specific inhibitors, high-throughput screening was carried out to search for compounds capable of 
selective potency toward E255V/T315I-expressing cells. To examine selectivity of drugs in relation 
to parental cells, selective Drug Sensitivity Scores (sDSS) were calculated using the software 
Breeze.  
Ba/F3 cells stably expressing E255V/T315I showed selective sensitivity to IAP SMAC mimetics 
(mimics of ‘small molecule second mitochondrial activator of caspase’) when compared to cells 
expressing T315I alone [Figure 18]. With the exception of mTOR inhibitors, which showed weak 
selectivity to E255V/T315I-expressing cells over cells expressing T315I alone [data not shown], no 
drug group displayed selective potency to cells expressing E255V/T315I over T315I-expressing 
cells. Notably, the IAP SMAC mimetic AT-406 exhibited selectivity to E255V/T315I-expressing 
cells (sDSS = 6,6) when compared to cells stably expressing T315I (sDSS = 0,8). The SMAC 
mimetics birinapant and LCL-161, likewise, displayed selective potency to cells expressing 
E255V/T315I (sDSS = 3,4 and 11,1, respectively) compared to T315I-expressing cells (sDSS = 0 
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and -0,2, respectively). The IC50s did not allow for strong conclusions to be made because the 
values suggested moderate resistance to E255V/T315I-expressing cells (IC50 = 350 nM, 124 nM, 
and 103 nM, for AT-406, birinapant, and LCL-161, respectively), but the values were nevertheless 
higher than they were for T315I-expressing cells (IC50 = 731 nM, 246 nM, and 526 nM, 
respectively). Note that SMAC mimetics did not show selective potency to E255V/T315I-
expressing cells over cells expressing BCR-ABL1. 
 
 
Figure 18: IAP SMAC mimetics displayed selective potency toward cells expressing E255V/T315I when 
compared to cells expressing T315I alone. Consider that the dose response curve for cells expressing 
E255V/T315I is closer to the y-axis in all cases, showing that a lower concentration of drug is needed to 
compromise cell viability of E255V/T315I cells than in cells expressing T315I alone. For simplicity, cell lines are 
referred to by the mutation they express. GraphPad Prism was used for data visualization. 
Another small group of compounds that showed potency toward E255V/T315I-expressing cells 
included two Hsp90 (Heat shock protein 90) inhibitors: CUDC-305 (sDSS = 5,5; IC50 = 141 nM) 
and radicicol (sDSS = 5,4; IC50 = 229 nM). However, selectivity over cells expressing T315I was 
ambiguous [data not shown]. Thus, these two small groups of drugs were further investigated in 
E255V/T315I-expressing cells in another cell-viability assay which contained seven selected 
inhibitors, including the three SMAC mimetics and two Hsp90 inhibitors. The assay was carried out 
in duplicate and analyzed with GraphPad Prism.  
The second screening with these inhibitors resulted in heterogeneous IC50s. When the IC50s of the 
three SMAC mimetics in E255V/T315I-expressing cells were considered, the average absolute 
fold-change between the two experiments was 2,9. However, the same comparison in cells 
expressing BCR-ABL1 (control cells) was inconsequential (1,5). Although results of the repeated 
screening with selected inhibitors remained inconclusive, SMAC mimetics continued to show 
consistent selectivity toward E255V/T315I-expressing cells over cells expressing T315I. Again, 
E255V/T315I-expressing cells displayed more sensitivity to AT-406, birinapant, and LCL-161 
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(IC50 = 170 nM, 37, and 31 nM, respectively) than to cells expressing T315I. No tested amount of 
the allosteric inhibitor asciminib could compromise cell viability in E255V/T315I-expressing cells.  
It is important to note that cells stably expressing E255V/T315I showed sensitivity to many general 
chemotherapy drugs. These compounds included the RNA and DNA synthesis inhibitor 
dactinomycin (IC50 = 0,7 nM), the mitotic inhibitor vinblastine (IC50 = 4 nM) and the antimetabolite 
floxuridine (IC50 = 11 nM), among others. Although these inhibitors are FDA approved and potent 
against E255V/T315I-expressing cells, finding compounds selective toward these highly resistant 
cells (as opposed to drugs targeting all rapidly dividing cells) goes a long way to minimize toxicity 
and lead to more targeted and efficient cancer therapy.  
 
2.1.4.6. Combining the SMAC mimetic LCL-161 and the allosteric inhibitor asciminib 
resulted in antagonism in cells expressing BCR-ABL1 E255V/T315I 
It was not known whether the E255V/T315I-expressing cells could be simultaneously and 
effectively targeted at the ATP-binding pocket as well as the myristoyl pocket. Thus, to find 
possible synergy, combinatorial treatment of E255V/T315I-expressing cells was carried out. ATP-
competitive inhibitors axitinib and ponatinib were combined with the ATP-noncompetitive inhibitor 
asciminib. Furthermore, considering that SMAC mimetics showed selective potency toward cells 
expressing E255V/T315I, asciminib was combined with the SMAC mimetic LCL-161. BCR-
ABL1-expressing cells were used as control and results were analyzed with the ZIP method using 
SynergyFinder. 
Instead of targeting the ABL1 kinase domain in a synergistic manner, SMAC mimetic LCL-161 in 
combination with the allosteric inhibitor asciminib had an antagonistic effect on E255V/T315I-
expressing cells [Figure 19]. The combined treatment in cells expressing E255V/T315I resulted in a 
ZIP synergy score of -3.2. This result is similar to the antagonistic effect of LCL-161 and asciminib 






Figure 19: Combinatorial treatment of the SMAC mimetic LCL-161 and the allosteric inhibitor asciminib 
resulted in antagonism in cells stably expressing E255V/T315I. (a) Drug-interaction heatmap of LCL-161 and 
asciminib in E255V/T315I-expressing cells. Green area refers to antagonism and pink area refers to synergy. Note 
that, due to different legends, the intensity of color indicates a different synergy score than does the corresponding 
color in Figure 15 (Section 2.1.4.3.); (b) Dose-response matrix of the combinatorial treatment. Results are shown 
as percent inhibition when compared to negative control. Data represent duplicates. 
 
Even though the ATP-noncompetitive inhibitor asciminib had no independent effect on 
E255V/T315I-expressing cells, combining asciminib with inhibitors that target the ATP-binding 
site resulted in synergy. Combining the TKI ponatinib and allosteric inhibitor asciminib in cells 
expressing E255V/T315I resulted in synergy (ZIP synergy score = 15,3), but in concentrations of 
ponatinib that show resistance (> 300 nM) [data not shown]. The tyrosine kinase inhibitor axitinib 
combined with asciminib had a synergistic effect (ZIP synergy score 6.4) centering on extremely 
high concentrations of axitinib (1000 nM) and asciminib (300-3000 nM) in E255V/T315I-
expressing cells [data not shown]. Although the ZIP synergy score appears high for both 
combinations in this cell line, the concentration of compounds needed to achieve that synergy is 
much too high to consider clinical relevance. Furthermore, it can be argued that, at high enough 
concentrations, any toxic chemical (drug) will compromise cell viability in these cells.  
All three combinations resulted in weak synergy in cells stably expressing BCR-ABL1. A modest 
but noticeable synergy (ZIP synergy score 2.7) could be seen between the kinase inhibitor axitinib 
and allosteric inhibitor asciminib in cells expressing BCR-ABL1. The strongest synergistic effect 
can be observed when combining 300 nM axitinib and 10 nM asciminib [data not shown]. The 
tyrosine kinase inhibitor ponatinib combined with asciminib revealed slight synergy (ZIP synergy 
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score 0.8) centered around the concentrations 10 nM for asciminib and 3 nM for ponatinib [data not 
shown]. Interestingly, combinatorial treatment of the IAP SMAC mimetic LCL-161 and asciminib 
exhibited small synergy that included low concentrations of asciminib (10 nM) but higher 
concentrations of LCL-161 (>250 nM) [data not shown]. It is worth noting that the concentration of 
asciminib needed to achieve synergy did not surpass 100 nM in any of the three duplicates, and 
centered around 10 nM in all cases. 
Several conclusions can be drawn from these results. First, the presence of mutations in the ABL1 
kinase domain, T315M and E255V/T315I, appears to alter the response of cells when compounds 
are combined. When ponatinib or axitinib are combined with asciminib, strong synergy can be 
achieved in cells expressing T315M or E255V/T315I, but only in high concentrations of either TKI. 
Although the combination produces synergy in BCR-ABL1-expressing cells, the synergy is faint. 
Interestingly, combining the SMAC mimetic LCL161 with asciminib in cells expressing BCR-
ABL1 resulted in synergy, yet the same combination in cells expressing T315M or E255V/T315I 
lead to antagonism. This discrepancy further supports the implication that the presence of a new 
amino acid in the ABL1 kinase domain of these cells alters drug-drug interaction. Second, no 
synergy was seen in high concentrations of any drug in cells expressing BCR-ABL1, whereas, if 
synergy occurred in the other two cell lines, it was stronger at higher concentrations. It is important 
to note that, although the synergy in cells expressing BCR-ABL1 was faint, it did occur in low 
concentrations, which implies possible clinical relevance.  
 
2.1.4.7. Axitinib shows selective potency against cells expressing BCR-ABL1 T315I   
Given the frequent adverse side-effects of the broad-range TKI ponatinib, the VEGFR inhibitor 
axitinib was included among the selected inhibitors that were used to treat cells stably expressing 
T315I. To this end, cells expressing T315I were constructed. To confirm the selective potency of 
axitinib on T315I-expressing cells and reproduce published findings, a cell-viability assay was 
carried out, and data were analyzed using GraphPad Prism.  
As has been shown previously, cells stably expressing T315I displayed selective sensitivity to the 
kinase inhibitor axitinib [Figure 20]. Cells stably expressing T315I exhibited more sensitivity 
toward axitinib (IC50 = 59 nM) than cells carrying BCR-ABL1 (IC50 = 219 nM) or T315M (IC50 = 





Figure 20: The effect of axitinib on cells stably expressing BCR-ABL1, T315I, T315M and E255V/T315I, 
respectively. For simplicity, cells stably expressing BCR-ABL1, T315I, T315M and E255V/T315I are referred to 
by the mutation they carry. Data represent three respective experiments.  
In comparison, only cells stably expressing BCR-ABL1 showed sensitivity to the TKI imatinib 
(IC50 = 117 nM). Cells stably expressing the respective oncogenes T315I, T315M, and 
E255V/T315I displayed complete resistance to imatinib (IC50 > 4000 nM for all three) [Figure 20a]. 
The broad-range TKI ponatinib showed high potency to cells expressing BCR-ABL1 and T315I 
(IC50 = 1 nM for both) when compared to cells expressing T315M (IC50 = 17 nM) and 
E255V/T315I (IC50 = 592 nM) [Figure 20b]. Notably, cells expressing T315I showed moderate 
resistance to the allosteric inhibitor GNF-2 (IC50 = 175 nM) [data not shown].  
 
  
Figure 20: Comparison of the sensitivity of cells expressing BCR-ABL1, T315I, T315M and E255V/T315I 
to the TKIs imatinib (a) and ponatinib (b). (a) Cells stably expressing the BCR-ABL1 plasmid are considerably 
more sensitive to imatinib than cells expressing T315I, T315M, or E255V/T315I; (b) Ponatinib exhibited potency 
toward cells expressing the BCR-ABL1 and T315I when compared to cells expressing T315M or E255V/T315I. 
Data represent three independent assays. 
When compared to the other cell lines, cells stably expressing BCR-ABL1 (control) showed most 
sensitivity to the 12 selected inhibitors. Cells expressing BCR-ABL1 exhibited most sensitivity to 
the TKIs dasatinib (IC50 = 0,4 nM), ponatinib (IC50 = 1 nM), bafetinib (IC50 = 4 nM), nilotinib (IC50 
= 8 nM), and imatinib (IC50 = 117 nM). Of the tested compounds, cells expressing BCR-ABL1 
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were least sensitive to the kinase inhibitors axitinib and saracatinib (IC50 = 275 nM), and the ATP-
noncompetitive inhibitor GNF-2 (IC50 = 577 nM) [data not shown]. Notably, cells stably expressing 
BCR-ABL1 showed selective sensitivity to the BRAF (serine/threonine protein kinase B-Raf) 
inhibitor CEP-32496 at IC50 = 24 nM (sDSS = 31,8). 
To find other potential compounds capable of selective potency toward cells expressing T315I, the 
cells were treated with inhibitors from > 50 drug classes in the FO4B and PKIS drug sets. As in 
previous assays, cell viability measurement was followed by analysis using Breeze and Graphpad 
Prism. Supporting the results of the first experiment, ponatinib and axitinib showed remarkable 
selectivity toward T315I-expressing cells (sDSS = 27 and 22, respectively). The cells showed 
resistance to imatinib, nilotinib, dasatinib, and bosutinib (IC50 > 1000 for all four). However, six 
compounds in the PKIS showed potency toward cells expressing T315I [data not shown]. The cells 
showed most sensitivity to the PKIS inhibitor GW683134A (IC50 = 86 nM), and all six compounds 
that displayed selectivity to T315I-expressing cells are known inhibitors of ABL1. Note that Ba/F3 
parental cells and not cells expressing BCR-ABL1 were used as control in the PKIS screening. 
T315I-expressing cells showed more sensitivity to the selected inhibitors than cells expressing 
T315M or E255V/T315I, but it is worth noting that, with the exception of ponatinib, no TKI 
approved to treat CML compromised cell viability in T315I-expressing cells in clinically relevant 
concentrations. However, the sensitivity of the cells to the TKI axitinib shows promise in treating 






2.1.5.1. Summary of Key Results 
Cells expressing the BCR-ABL1 T315M mutation displayed resistance to all first- and second-
generation TKIs, and moderate resistance to ponatinib. However, as a novel finding, several mTOR 
and topoisomerase II inhibitors selectively compromised cell viability in T315M-expressing cells. 
Combination testing revealed strong synthetic lethality when high concentrations of the ATP-
noncompetitive inhibitor asciminib and ponatinib were combined in these cells. Next, cells stably 
expressing E255V/T315I showed complete resistance to all approved TKIs. The cells were affected 
by general chemotherapy but few compounds showed selectivity. Among them, three SMAC 
mimetics displayed selective potency to E255V/T315I-expressing cells over cells expressing T315I. 
As reported previously, cells stably expressing the gatekeeper mutation T315I displayed sensitivity 
to the TKIs ponatinib and axitinib, but the first- and second-generation TKIs failed to induce 
compromised cell viability in T315I-expressing cells. All five TKIs induced loss of cell viability in 
cells stably expressing BCR-ABL1 in clinically relevant concentrations. Interestingly, the BRAF 
inhibitor CEP-32496 displayed selective potency toward cells expressing BCR-ABL1.  
 
2.1.5.2. Novel finding: Inhibitors of mTOR and topoisomerase II showed selective potency 
toward T315M-expressing cells 
As a novel finding, inhibitors of the mTOR pathway and topoisomerase II induced cell viability loss 
in T315M-expressing cells. This result was supported by two screenings with two separate T315M-
expressing cell populations.  
The reason behind the selectivity of topoisomerase II inhibitors toward cells expressing T315M 
over cells carrying T315I or E255V/T315I can be speculated. Although the polar threonine is 
replaced by the non-polar methionine in amino acid position 315 in the ABL1 kinase domain of 
cells expressing T315M (Gorre et al., 2001), both BCR-ABL1-expressing cells and T315M-
expressing cells showed selective sensitivity toward inhibitors of topoisomerase II. Thus, the 
threonine to methionine substitution is unlikely to be the cause of sensitivity of cells expressing 
T315M cells to topoisomerase II inhibitors. It is reasonable to conclude that the presence of 
methionine instead of isoleucine might imply changes in pathways within cells carrying T315M. 
Moreover, a potential change in pathways with similar implications—sensitivity to topoisomerase 
II—does not appear to occur when the T315I mutation is accompanied by another point mutation, 
E255V, because inhibitors of topoisomerase II did not show selective potency toward cells stably 
expressing E255V/T315I.  
Uncontrolled activation of the PI3K (phosphatidylinositol 3-kinase)/Akt (protein kinase B)/mTOR 
pathway has been detected in CML. Aberrant mTOR activity could enable drug resistance, but it 
could also be an effective target for inhibitors (Dinner and Platanias, 2016). Suppressing the 
Akt/mTOR pathway with the anesthetic propofol has been shown to improve the efficacy of TKIs 
in CML (Tan et al., 2017). In addition, two respective clinical trials have combined imatinib with 
the mTOR inhibitors everolimus and temsirolimus in treating CML (ClinicalTrials.gov ID: 
#NCT00093639 and #NCT00101088). Although no results have been published, this appears to be 
an active area of research. Considering the selective sensitivity of cells expressing BCR-ABL1 or 
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T315M to mTOR inhibitors, it is possible that the mTOR signaling that may be constitutively 
activated in cells expressing BCR-ABL1 is also activated in cells expressing T315M. The 
occurrence of T315M may affect the PI3K/Akt/mTOR pathway in a way that is dissimilar to cells 
stably expressing T315I. Another possibility is that the presence of T315M returns the 
PI3K/Akt/mTOR pathway back to its “original” constitutively active state seen in cells expressing 
the BCR-ABL1. Given that mTOR inhibitors showed potency for T315M-expressing cells only 
comparable to BCR-ABL1-expressing cells, combining an mTOR inhibitor with a TKI might 
induce loss of cell viability in a synergistic way in either cell line. 
 
2.1.5.3. Combination testing resulted in synthetic lethality for cells expressing T315M 
Considering that compound mutations containing T315I have been linked to ponatinib-failure 
(Zabriskie et al., 2014), it would be reasonable to conclude that combining TKIs targeting the ATP-
binding pocket with the ATP-noncompetitive asciminib would result in synergy in cells expressing 
T315M or E255V/T315I. Asciminib has a different pattern of resistance mutations than second-
generation TKIs do. The allosteric inhibitor has been shown to be active against all mutations in the 
ATP-binding site while inhibitors targeting the ATP-binding site showed activity against all 
asciminib-resistant mutations. In spite of the (expected) acquired resistance in mice treated with 
single compounds, combining the TKI nilotinib with the allosteric inhibitor asciminib resulted in 
complete control of leukemia and elimination of CML xenograft tumors. Furthermore, leukemia did 
not recur after combination therapy had ended (Wylie et al., 2017).  
Combining two inhibitors with non-overlapping resistance profiles that target different sites of 
ABL1 has tremendous potential. Indeed, combining asciminib and ponatinib in treating cells 
expressing T315M resulted in such high ZIP synergy score (36,5) as to suggest using this 
combination as the positive control for synergy. In this case, combining 30 nM of ponatinib with 
100 nM of asciminib has little clinical relevance because both concentrations are too high for 
safety. 30 nM of ponatinib alone is considered to be “moderately resistant” by Zabriskie et al., 
2014. Nevertheless, combining all available TKIs with all available allosteric inhibitors might lead 
to combinations that compromise cell viability in cells stably expressing T315M or E255V/T315I in 
concentrations low enough to imply clinical relevance.  
 
2.1.5.4. Cells expressing T315M showed moderate resistance to the broad-range TKI 
ponatinib 
Cells stably expressing T315M showed resistance to the four first- and second-generation TKIs, but 
the cells showed more sensitivity toward ponatinib (IC50 = 44,5 nM, an average of four 
experiments) when compared to results published by Lasater et al., 2016 (IC50 = 204 nM). 
According to Lasater et al. (2016), the T315M mutation is highly resistant to ponatinib because the 
hydrophobic side chains of T315M are too big to allow ponatinib to bind to the ATP-binding 
pocket. Although the average of three replicates on the new T315M custom plates reveals a higher 
result (IC50 = 115 nM) and remains consistent within the experiment, cells expressing T315M were 
found to be more sensitive to ponatinib than previous publications suggest (Zabriskie et al., 2014; 
Lasater et al., 2016). Regardless of the difference between the published sensitivity to ponatinib and 
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one described here, even the IC50 achieved in this thesis calculated as an average of all experiments 
(IC50 = 75 nM) would be too high to consider in a clinical setting (for cells expressing T315I, IC50 = 
8 nM), especially when the side effects of ponatinib are considered (Cassuto and Dufies et al., 
2012; Jain et al., 2015).  
 
2.1.5.5. IAP SMAC mimetics show selective potency toward cells expressing E255V/T315I 
over cells carrying T315I alone 
Although few drugs were selective toward E255V/T315I-expressing cells, three IAP SMAC 
mimetics showed selectivity when compared to cells stably expressing T315I. In the initial 
screening, cells expressing E255V/T315I displayed complete resistance to all TKIs, including 
ponatinib. The reason behind the lower affinity of ponatinib to the compound mutation compared to 
the gatekeeper mutation T315I alone has been suggested to be the re-orientation of the P-loop in 
order to fit the hydrophobic valine side chain in position 255 (Zabriskie et al., 2014). Although the 
high-throughput screening found general chemotherapy drugs capable of inducing loss of cell 
viability in cells carrying this highly resistant mutation, few compounds showed selectivity to these 
cells. Among them, three IAP SMAC mimetics stood out: AT-406, LCL161, and birinapant. A 
repeated three-day viability assay gave heterogeneous results regarding the IC50s of these drugs, but 
both screenings showed consistent selectivity of IAP SMAC mimetics to cells expressing 
E255V/T315I over cells expressing T315I alone.  
The selective potency of several SMAC mimetics to E255V/T315I-expressing cells over cells that 
express T315I alone is an exciting prospect. No other drug class showed such a marked and 
consistent selectivity to cells expressing E255V/T315I over T315I. Moreover, to the best of our 
knowledge, this selectivity has not been shown before. Importantly, SMAC mimetics displayed 
selective potency to E255V/T315I-expressing cells over T315I-expressing cells even when the 
heterogeneous IC50 values of the second experiment were considered.  
However, a few caveats have to be considered. First and foremost, the three SMAC mimetics were 
tested only once in cells expressing T315I in the FO4B screening. The second screening included 
cells expressing BCR-ABL1 as control. Given the difference in results of the first and second assay, 
it is not unreasonable to question whether the drugs would also display less potency to T315I-
expressing cells in the second screening. Second, only three SMAC mimetics were included in 
FO4B screening and in this thesis. It is possible that this selective potency, if supported by further 
evidence, is limited to only a few SMAC mimetics. And third, even if the finding is supported by 
further evidence, the concentrations of drugs needed to achieve cell viability loss in mouse cells 
might not translate well to drug concentrations needed by humans. All in all, however, this 
supposed selectivity is an exciting discovery and should be considered for further investigation.  
IAPs are expressed in many cancers, and SMAC mimetics induce cell death by imitating the IAP 
antagonist Smac (Fulda, 2015). This selectivity, if true, could be a pathway change affected by the 
presence of valine at position 255. These pathways might be associated with an abnormal IAP 
activity which could be changing the sensitivity of these cells to SMAC mimetics. However, further 
research is necessary to determine if this result can be repeated, and if so, how much clinical 




2.1.5.6. Combining the TKI ponatinib with the allosteric inhibitor asciminib resulted in 
synergy at low concentrations of drugs in cells expressing BCR-ABL1 
Regardless of the low ZIP synergy score in BCR-ABL1-expressing cells when the TKI ponatinib 
and the allosteric inhibitor asciminib were combined, synergy occurred at low concentrations of 
either drug. Considering that ATP-competitive and ATP-noncompetitive inhibitors have been 
shown to have non-overlapping mutation profiles (Wylie et al., 2017), low concentration of 
ponatinib combined with asciminib might have value in clinical setting as means to prevent drug-
resistance that is driven by point mutations in the ABL1 kinase domain.  
 
2.1.5.7. T315I-expressing cells showed sensitivity to the TKI axitinib 
As published by Pemovska et al. (2015) and shown here, cells stably expressing T315I exhibited 
sensitivity to the VEGFR inhibitor axitinib (IC50 = 59 nM). In addition, the result for the broad-
range TKI ponatinib in these cells falls in line with that of Cassuto and Dufies et al. (2012), who 
found ponatinib to be capable of inducing loss of cell viability at a similar concentration (IC50 = 8 
nM). Moreover, as shown previously by Redaelli et al. (2009), cells stably expressing T315I 
showed resistance to first- and second-generation TKIs (imatinib, nilotinib, dasatinib, bosutinib). In 
comparison to cells stably expressing T315M or E255V/T315I, the problem of resistance in T315I-
expressing cells might not appear as complex now that ponatinib is in the market, but the adverse 
side effects of the drug and lack of FDA-approved alternatives must be considered when comparing 
the mutations. Furthermore, given that the gatekeeper mutation T315I is considered to be the most 
frequent mutation to occur in CML patients (COSMIC database) and that the prevalence of CML is 
expected to rise six-fold by 2050 (Huang et al., 2012), the importance of finding an alternative to 
ponatinib cannot be overstated. 
 
2.1.5.8. Conclusions 
Finding drugs with high affinity toward cells expressing these three mutations, especially CML 
patients carrying these mutations, will be a challenge. Treating drug-resistance as well as 
anticipating its occurrence may often have to be considered together. First, successful and long-term 
inhibition of cells carrying highly resistant mutations may have to include combination testing to 
target several sites of the molecule and find drugs that act in synergy. Second, crystallography of 
the ABL1 kinase domains of T315M and E255V/T315I may be needed to fully understand the 
molecular dynamics of drug-binding and the implications of each mutation. The structure, 
chemistry and size of each mutation may be incompatible with drug-binding. Therefore, 
understanding the characteristics of each mutation may allow computer modeling to design for an 
inhibitor that binds and inhibits the constitutively active ABL1 kinase domain. Third, CML patient 
samples would be invaluable in testing drugs and combinations of drugs to establish the efficacy of 








The kinase inhibitor axitinib has not only been shown to have high affinity for T315I in kinase 
assays (Davis et al., 2011), the inhibitor has also shown clinical activity in a CML patient carrying 
T315I (Pemovska et al., 2015). Considering the frequent adverse side effects that accompany 
ponatinib-treatment (Cortes et al., 2013), axitinib shows promise for CML patients carrying the 
T315I mutation. However, mutations that enable cells to develop resistance to axitinib have so far 
remained unexplored. Knowing which point mutations enable axitinib-resistance is key to 
understanding how to address resistance in CML patients. To this end, Kesarwani et al. (2014) have 
successfully introduced a library of random mutations in JAK2 (Janus kinase 2) kinase domain 
prior to transduction of Ba/F3 cells and inducing drug-resistance. All of the mutations they 
identified using this method were later observed in patients (Kesarwani et al., 2014). Therefore, in 
my study Ba/F3 cells were infected with retroviruses containing a library of random mutations 
introduced to BCR-ABL1 T315I and treated with axitinib to observe which mutations are likely to 
emerge as a result of axitinib-resistance.  
 
2.2.2. Materials 
All cell lines were maintained in a humidified incubator containing 5% CO2 at 37 °C (see Section 
2.1.2). The XL1-Red bacterial strain (from Escherichia coli) and β-mercaptoethanol were 
purchased from Agilent Technologies (#200129) and stored at -80 °C. XL1-Red competent cells are 
characterized by three impaired primary DNA repair pathways, which create an approximate 5000-
fold increase in mutation rate when compared to wild-type (Agilent Technologies, #200129). SOC 
medium (Super Optimal broth with Catabolite repression) was kindly provided by Daria Bulanova.  
 
2.2.3. Methods 
2.2.3.1. XL-1 Red Mutagenesis  
To introduce random mutations in a BCR-ABL1 gene containing the T315I mutation, an XL1-Red 
bacterial strain was used according to a modified protocol by Agilent Technologies (#200129). 
Note that 100 ng of DNA (pMIG-BCR-ABL1 T315I) was used in the experiment. The plates were 
incubated for 30 h at 37 °C. No colonies grew on the control plate. Colonies containing the random 
mutations introduced to pMIG-BCR-ABL1 T315I were collected prior to DNA isolation using the 
protocol provided by QIAGEN Plasmid Plus Midi Kit (Qiagen; #12943). 
 
2.2.3.2. Construction of cell lines and selection of drug-resistant cells  
Ba/F3 parental cells were infected with a retrovirus from the virus packaging cell line CRL-11654 
containing the random plasmid collection introduced to pMIG-BCR-ABL1 T315I using the 
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protocol in Section 2.1.3.1. Selection was complete 10 days after the removal of IL-3 from the 
growth medium.  
Ba/F3 cells stably expressing the randomized plasmid collection introduced to BCR-ABL1 T315I 
were treated with axitinib in order to select for an axitinib-resistant population. 8,3 x 105 cells/well 
on a 6-well plate were divided into three sections based on the concentration of axitinib: 0 nM 
(DMSO), 200 nM, and 500 nM. DMSO volume corresponding to the amount of axitinib needed to 
achieve the highest concentration (500 nM) of drug served as the control. Rapid growth of Ba/F3 
cells stably expressing mutagenized BCR-ABL1 T315I in wells containing 500 nM of axitinib was 
detected 20-25 days after the beginning of axitinib-treatment. 
 
2.2.3.3. Drug-screening of axitinib-resistant cells  
A three-day CellTiter-Glo Luminescent Cell Viability Assay was performed on Ba/F3 cells stably 
expressing (1) BCR-ABL1 T315I, (2) random mutations introduced to BCR-ABL1 T315I, and (3) 
axitinib-treated cells stably expressing random mutations introduced to BCR-ABL1 T315I 
according to the protocol described in Section 2.1.3.2.-2. The 384-well plate layout, originally 
designed by Tea Pemovska, was modified to contain the ATP-noncompetitive inhibitor asciminib 
(0,1-1000 nM) in addition to 10 compounds listed in Figure 12 (excluding AT9283 and rebastinib).  
 
2.2.3.4. Sequencing the kinase mutations that allow resistance to axitinib 
QIAprep Spin Miniprep Kit was used to isolate plasmid DNA from the three cell lines according to 
the protocol provided by Qiagen (#27106). Amplicon sequencing of the ABL1 kinase domain 
helped detect the mutations that emerged under treatment with axitinib. Amplicon sequencing was 
performed by the FIMM Sequencing Unit with the following locus-specific primers:  
ABL1_cDNA_1-F   CCATTATCCAGCCCCAAAG 
ABL1_cDNA_1-R   CCTTCACCAAGTGGTTCTCC 
ABL1_cDNA_2-F   AGATCTTGCTGCCCGAAACT 
ABL1_cDNA_2-R   CCTGCAGCAAGGTACTCACA 
 
The following adapter primers were attached to the locus specific primers (5’-3’):  
F-primers     ACACTCTTTCCCTACACGACGCTCTTCCGATCT 
R-primers     AGACGTGTGCTCTTCCGATCT 
 
The standard PCR (polymerase chain reaction) protocol by Finnzymes Phusion High-Fidelity PCR 
Master Mix (Thermo Fisher Scientific; #F531L) was carried out. Note that the PCR process 
included a total of 30 cycles and that annealing occurred at 60 °C. Basic Local Alignment Search 





Although the broad-range TKI ponatinib shows potency toward cells carrying T315I, adverse 
effects have been shown to occur in patients (Jain et al., 2015). As a potential alternative, the 
VEGFR inhibitor axitinib has displayed clinical activity in a T315I-positive CML patient 
(Pemovska et al., 2015). Given that Kesarwani et al. (2014) have successfully predicted clinically 
relevant mutations by expressing a library of random mutations in a Ba/F3 cell model and 
sequencing the kinase domain after treating the cells with their drug of interest, this approach was 
used to predict mutations that might arise after axitinib-treatment.  
 
2.2.4.1. Cells stably expressing BCR-ABL1 T315I displayed sensitivity to asciminib and 
axitinib 
Three different cell lines were constructed and treated with the selected inhibitors: cells stably 
expressing (1) BCR-ABL1 T315I, (2) the library of random mutations introduced to BCR-ABL1 
T315I, or (3) axitinib-resistant cells expressing random mutations introduced to BCR-ABL1 T315I. 
A three-day cell viability assay using Cell-Titer Glo in 384-well format was carried out. Next, to 
determine sensitivity of a cell line to a particular drug, half-maximal inhibitory concentrations were 
calculated using GraphPad Prism. 
Of the three cell lines, cells expressing T315I displayed the most sensitivity to the selected 
compounds [Figure 21]. Notably, cells stably expressing T315I showed sensitivity toward the 
kinase inhibitor axitinib (IC50 = 48 nM) and the allosteric inhibitor asciminib (IC50 = 1 nM). In 
addition, the TKIs ponatinib (IC50 = 1 nM) and dasatinib (IC50 = 5 nM) exhibited potency toward 
T315I-expressing cells. The cells displayed moderate resistance to the allosteric inhibitor GNF-2 
(IC50 = 81 nM), and the TKIs danusertib (IC50 = 179 nM) and bosutinib (IC50 = 514 nM). T315I-
expressing cells showed complete resistance to nilotinib, saracatinib, imatinib, and bafetinib (IC50 > 







Figure 21: Cells stably expressing T315I showed sensitivity to the allosteric inhibitor asciminib, the kinase 
inhibitor axitinib, and the TKIs ponatinib and dasatinib. The cells exhibited the most sensitivity toward the 
broad-range TKI ponatinib and the ATP-noncompetitive inhibitor asciminib, moderate resistance to the allosteric 
inhibitor GNF-2, the TKIs danusertib and bosutinib, and complete resistance to nilotinib, saracatinib, imatinib, 
and bafetinib. Error bars indicate standard deviation between two replicates.  
Of note, this finding further supports the sensitivity of T315I-expressing cells to axitinib, but it also 
highlights the potential of the ATP-noncompetitive inhibitor asciminib to compromise the viability 
of cells expressing the gatekeeper mutation. However, the apparent potency of dasatinib to T315I-
expressing cells is a clear outlier when compared to the previous four experiments, in which no IC50 
could be reached in T315I-expressing cells. With this exception, the results of this experiment 
compare favorably to the previous experiments and can be considered a reliable control for cells 
expressing the random mutations introduced to BCR-ABL1 T315I, and axitinib-treated cells 
expressing random mutations introduced to BCR-ABL1 T315I. 
 
2.2.4.2. Cells stably expressing random mutations introduced to BCR-ABL1 T315I displayed 
more resistance to selected inhibitors than T315I-expressing cells 
Cells stably expressing random mutations introduced to BCR-ABL1 T315I showed more resistance 
to all tested compounds when compared to T315I-expressing cells [Figure 22]. The cells exhibited 
moderate resistance to ponatinib (IC50 = 86 nM), the allosteric inhibitor asciminib (IC50 = 226 nM), 
and the kinase inhibitors danusertib (IC50 = 242 nM) and axitinib (IC50 = 303 nM). The cells showed 
resistance to saracatinib, imatinib, and bosutinib (IC50 > 1000 nM), and the allosteric inhibitor GNF-





Figure 22: Cells stably expressing the random mutations introduced to BCR-ABL1 T315I showed more 
resistance to the tested compounds than cells expressing the T315I alone. Ponatinib, although resistant, 
showed most sensitivity to cells expressing the collection of random mutations introduced to BCR-ABL1 T315I. 
The allosteric inhibitor asciminib, and the kinase inhibitors danusertib and axitinib showed moderate resistance to 
cells carrying the mutagenized BCR-ABL1 T315I. The cells displayed complete resistance to bosutinib, imatinib, 
saracatinib, and GNF-2. Lines indicate standard deviation within duplicates. 
 
2.2.4.3. Axitinib-resistant cells expressing random mutations introduced to BCR-ABL1 T315I 
conferred complete resistance to selected inhibitors  
Axitinib-resistant cells expressing random mutations introduced to BCR-ABL1 T315I showed 
complete resistance to all tested inhibitors [Figure 23]. Once more, the broad-range TKI ponatinib 
showed potency to the cells at the lowest concentration of drug (IC50 = 646 nM). The cells were 
completely resistant to the TKIs danusertib, saracatinib, imatinib, and bosutinib (IC50 > 1000 nM for 
all four). Interestingly, although the cells displayed resistance to axitinib, axitinib still induced loss 
of cell viability (IC50 > 1000 nM). No IC50 could be reached for nilotinib, dasatinib, bafetinib, GNF-





Figure 23: Axitinib-treated cells expressing mutagenized BCR-ABL1 T315I conferred resistance to all 
tested inhibitors. The TKI ponatinib showed most potency to axitinib-resistant, mutagenized BCR-ABL1 T315I-
expressing cells. The cells showed complete resistance to danusertib, saracatinib, imatinib, bosutinib, and axitinib. 
Nilotinib, dasatinib, bafetinib, GNF-2, and asciminib failed to show potency to axitinib-resistant, mutagenized 
BCR-ABL1 T315I-expressing cells in any measured concentration. Note that, when compared to cells expressing 
BCR-ABL1 T315I or mutagenized BCR-ABL1 T315I, more drug is needed to reach the IC50 and, therefore, the 
dose response curves have shifted to the right. Standard deviation within two replicates is indicated by lines.  
 
2.2.4.4. Cells expressing random mutations introduced to BCR-ABL1 T315I showed 
remarkable similarities to T315M-expressing cells 
Cells carrying the mutagenized BCR-ABL1 T315I showed remarkable similarities to cells 
expressing T315M [Table 3]. Two exceptions were observed. First, the aurora kinase inhibitor 
danusertib compromised cell viability in cells expressing the mutagenized BCR-ABL1 T315I at 242 
nM when compared to >1000 nM for cells expressing T315M. Second, the allosteric inhibitor 
asciminib showed more potency toward cells expressing random mutations introduced to BCR-
ABL1 T315I (IC50 = 226 nM) than toward T315M-expressing cells (IC50 > 1000 nM). However, 
both cell lines showed sensitivity in similar concentrations to all the other selected inhibitors. Table 
3 illustrates the increasing resistance of cells expressing random mutations introduced to BCR-











Table 3: Sensitivity of cells stably expressing BCR-ABL1 T315I (T315I), cells stably expressing 
mutagenized BCR-ABL1 T315I (mut. T315I), and axitinib-treated cells stably expressing mutagenized 
BCR-ABL1 T315I (axi-res. mut. T315I), to selected inhibitors. T315M shows results of the effect of selected 
inhibitors on cells expressing T315M described in Section 2.1.4.1., and asciminib in Section 2.1.4.2. Cells 
expressing random mutations introduced to BCR-ABL1 T315I (mut. T315I) appear highly similar to cells 
expressing T315M.  
 
IC50 – half-maximal inhibitory concentration; nM – nanomoles; N/A – IC50 could not be reached with the 
measured concentrations 
 
Amplicon sequencing confirmed the nucleotide substitution C -> T (99,9% of sequences) that 
defines the change from threonine to isoleucine in the ABL1 kinase domain of T315I-expressing 
cells. However, cells previously thought to be stably expressing T315I plasmid collection with 
random mutations were revealed to be expressing primarily two point mutations that are present in 
T315M: C -> T substitution (threonine to isoleucine), and the following T -> G substitution 
(isoleucine to methionine) in amino acid position 315, both in 99,8% of sequences. Two less 
frequent mutations occurred in these sequences in two distinct locations. First, C -> G substitution 
was found at amino acid position 420 (TCC -> TCG), but both DNA codons code for serine. 
Second, another C -> G substitution occurred at amino acid position 422 (GTC -> GTG), and, as 
with the previous substitution, both codons encode valine. The C -> G substitutions in amino acid 
positions 420 and 422 occurred in 2,2% and 2,1% of sequences, respectively. Therefore, although 
the nucleotides changed, the encoded amino acids remained the same. 
Sequencing of the ABL1 kinase domain from axitinib-resistant cells expressing the random plasmid 
collection introduced to T315I also revealed nucleotide substitutions characteristic of T315M: C -> 
T substitution in 99,8% of sequences and T -> G substitution in 99,6% of sequences. However, the 
two mutations that were observed less frequently in cells expressing the random plasmid collection 




2.2.5.1. Summary of Key Results 
Cells stably expressing T315I showed sensitivity to the VEGFR inhibitor axitinib (IC50 = 48 nM) 
and the allosteric inhibitor asciminib (IC50 = 1 nM). Cells expressing random mutations introduced 
to BCR-ABL1 T315I displayed more resistance to all tested compounds when compared to T315I-
expressing cells. Also, the sensitivity of cells carrying mutagenized BCR-ABL1 T315I showed 
remarkable similarity to cells expressing T315M. Indeed, amplicon sequencing of the ABL1 kinase 
domain of cells expressing the random mutations introduced to BCR-ABL1 T315I revealed that 
99,8% of sequences contained the missense mutations C -> T and T -> G (in amino acid position 
315) characteristic of T315M. Axitinib-treated cells expressing the random mutations introduced to 
BCR-ABL1 T315I conferred resistance to all tested compounds. In addition, sequencing of the 
ABL1 kinase domain of these cells revealed the same two point mutations present in cells 
expressing T315M. Yet, the two mutations that were observed less frequently in cells expressing 
the mutagenized T315I(M) were not found in the ABL1 kinase domain of axitinib-treated cells.  
 
2.2.5.2. Mutations characteristic of T315M appear to have occurred as a result of random 
mutagenesis of the T315I plasmid 
Given the success of Kesarwani et al. (2014) to anticipate clinically relevant drug-resistant 
mutations by sequencing drug-resistant Ba/F3 cells expressing random mutations, creating an 
axitinib-resistant population of cells expressing mutagenized T315I was expected to reveal point 
mutations that arise as a result of axitinib-resistance. 
However, amplicon sequencing of the ABL1 kinase domain revealed that instead of a library of 
random mutations, nucleotide substitutions were limited to four. Two of these are characteristic of 
T315M (ACT -> ATT -> ATG) present in 99,8% of sequences, and the other two occur infrequently 
and have no effect on the amino acid that is being produced. The reasons for the emergence of 
mutations characteristic of T315M could be as follows: (1) either the one nucleotide substitution 
that is needed between isoleucine and methionine (ATT -> ATG) is so likely to happen in random 
mutagenesis that this occurred in most bacterial cells in this study; (2) the bacterial cells that 
received the necessary nucleotide substitution for T315M outnumbered colonies containing other 
mutations; (3) an error occurred in the dispensing of the pMIG-BCR-ABL1 T315I and T315M 
plasmid was chosen instead. Although it is possible, the last option does not seem likely since the 
same pMIG-BCR-ABL1 T315I plasmid was used to create Ba/F3 cells stably expressing pMIG-
BCR-ABL1 T315I, which sequencing showed to have only the C -> T (ACT -> ATT) nucleotide 
substitution characteristic of T315I at 99,9% frequency.  
The lack of random mutations as a result of random mutagenesis of the pMIG-BCR-ABL1 T315I 
plasmid allows limited conclusions to be drawn. To better understand what caused the T315M 
mutation to arise as a result of mutagenizing pMIG-BCR-ABL1 T315I, this experiment should be 
repeated. If the bacterial cells containing the T315M mutation outnumber the other random 
mutations over time, limiting the incubation time to 18 or 24 hours might help to understand the 
ratio of mutations prior to T315M outnumbering the others. Most importantly, repeating the full 
experiment might give insight into which mutations are (1) likely to arise as a result of axitinib-
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treatment, and (2) sensitive to available inhibitors. If, however, the single nucleotide substitution 
allowing T315I to become T315M is so likely to happen in random mutagenesis of the pMIG-BCR-
ABL1 T315I plasmid that T315M would always be the most frequent mutation to arise, another 
method for creating mutations in the kinase domain of BCR-ABL1 T315I should be considered.  
 
2.2.5.3. The TKI axitinib and the allosteric inhibitor asciminib show potency to T315I-
expressing cells 
As expected, cells stably expressing T315I showed selective sensitivity toward the VEGFR 
inhibitor axitinib (IC50 = 48 nM). Notably, however, the cells also showed sensitivity to the 
allosteric inhibitor asciminib (IC50 = 1 nM), which targets the myristoyl pocket of ABL1 instead of 
the ATP-binding pocket, as has been shown previously by Wylie et al. (2017). As seen in Aim 1, 
asciminib alone failed to induce cell viability loss in either T315M-expressing or E255V/T315I-
expressing cells. However, asciminib showed powerful synergy in combination with ponatinib in 
cells expressing T315M, further highlighting the importance of combination treatment in targeting 
the ABL1 kinase domain.  
 
2.2.5.4. Conclusions 
Although Kesarwani et al. (2014) successfully predicted clinically relevant drug-resistant mutations 
by sequencing the kinase domains of drug-resistant Ba/F3 cells expressing random mutations, this 
approach failed to provide potential mutations emerging as a result of axitinib-resistance in this 
study. However, this experiment supported several findings. First, the consistency with which the 
TKI axitinib continued to display selective potency toward T315I-expressing cells encourages 
consideration of this inhibitor as an alternative to ponatinib. And second, the ATP-noncompetitive 
inhibitor asciminib, which did not achieve IC50s in cells expressing T315M or E255V/T315I, 
showed remarkable potency toward T315I-expressing cells. In conclusion, the potency of axitinib 
and asciminib to T315I-expressing cells can be considered the silver lining of this experiment, 
especially considering the adverse side effects of ponatinib and the highly resistant mutations found 
to occur as a result of ponatinib-treatment. 
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3. Conclusions   
 
Successful first-line therapy for CML with tyrosine kinase inhibitors has resulted in improved 
prognosis for the malignancy for nearly two decades (Bower et al., 2016). Although the disease is 
relatively rare and the incidence of CML has not been shown to increase, the prevalence of CML is 
expected to rise by more than six-fold by the year 2050 (Huang et al., 2012). Patients who had few 
options prior to tyrosine kinase inhibitor therapy are now able to live nearly the lifespan of a healthy 
individual (Bower et al., 2016). However, drug-resistance due to point mutations has been 
estimated to occur in up to 50% of imatinib-refractory CML patients (Jabbour et al., 2011), which 
poses a severe problem considering the increasing prevalence of the disease. Nearly a hundred 
mutations have been observed in the tyrosine kinase domain of ABL1 (Jabbour et al., 2011), and 
among them are the T315I, T315M, and E255V/T315I.  
As a novel discovery, cells stably expressing BCR-ABL1 T315M showed selective sensitivity 
toward inhibitors of topoisomerase II and mTOR. Eleven inhibitors of the mTOR pathway and nine 
inhibitors of topoisomerase II showed higher selective Drug Sensitivity Scores (sDSS) for cells 
stably expressing BCR-ABL1 T315M than for cells expressing BCR-ABL1 T315I or 
E255V/T315I. The sDSS values were comparable to cells expressing BCR-ABL1, which implies a 
possible difference in pathway signaling when isoleucine has been substituted with methionine. The 
finding opens the possibility of combining mTOR inhibitors with TKIs to induce loss of cell 
viability in cells expressing BCR-ABL1 T315M. Combination treatment of the allosteric inhibitor 
asciminib and broad-range TKI ponatinib in cells expressing BCR-ABL1 T315M resulted in 
unprecedented synthetic lethality. The ZIP synergy score could be suggestive of using this cell line 
and combination of drugs as the positive control for synergy. Moreover, combining other TKIs with 
ATP-noncompetitive inhibitors may lead to finding a combination that targets cells expressing 
BCR-ABL1 T315M in clinically relevant concentrations.  
Cells stably expressing BCR-ABL1 E255V/T315I exhibited incredibly high resistance to all TKIs. 
Although general chemotherapy drugs compromised cell viability in cells carrying the double 
mutation, few drugs showed selective potency toward these cells. Among these were three IAP 
SMAC mimetics: AT-406, LCL161, and birinapant showed selectivity over cells expressing T315I. 
However, it is important to note that the experiment was performed once in T315I-expressing cells 
and would have to be repeated to draw stronger conclusions from the finding. Furthermore, treating 
E255V/T315I-expressing cells with both asciminib and ponatinib resulted in synergy, but in 
incredibly high concentrations. Because compound mutations that contain T315I have been linked 
to ponatinib-failure (Zabriskie et al., 2014), combining the non-ATP inhibitors with inhibitors that 
target the ATP-binding site could lead to synergy capable of inducing cell viability loss in these 
cells in concentrations that are clinically useful.  
The gatekeeper mutation T315I, considered to be the most frequent point mutation in CML 
(COSMIC database), occurs in up to 20% of TKI-resistant patients (Soverini et al., 2009). Given 
that the VEGFR inhibitor axitinib has shown clinical activity in a CML patient carrying T315I 
(Pemovska et al., 2015), a model system was set up that would allow to predict mutations that 
enable axitinib-resistance in patients. Although the method allowed Kesarwani et al. (2014) to 
accurately predict clinically relevant mutations, this approach failed to provide mutations emerging 
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as a result of axitinib-resistance in this study. For further investigation, another method for creating 
random mutations in the BCR-ABL1 T315I kinase domain should be considered.  
Importantly, the allosteric inhibitor asciminib showed high potency toward cells stably expressing 
BCR-ABL1 T315I (IC50 = 1 nM), as has been shown previously by Wylie et al. (2017). This ATP-
noncompetitive inhibitor presents an exciting opportunity for combination testing to target both the 
myristoyl site with asciminib and the ATP-binding pocket with an ATP competitive inhibitor. This 
prospect is particularly exciting because mutations that emerge as a result of asciminib-treatment 
and as a result of TKI-treatment do not overlap (Wylie et al., 2017). Moreover, combining 
asciminib and ponatinib in cells expressing BCR-ABL1 resulted in synergy in low concentrations of 
either drug, implying clinical relevance.  
The three mutations occur seldom in a rare disease, but it is important to remember that even rare 
mutations will become more frequent as the prevalence of CML increases. Finding solutions may 
be possible by drug-repurposing, finding synergy in combination therapy, or solving the structures 
of the kinase domains containing the drug-resistant mutations to design new drugs. Solutions are 
likely to be found one step at a time.  
This study focused on ways to overcome drug-resistance that is caused by point mutations in CML. 
However, drug target alteration, although important, is only a fraction of the elaborate machinery of 
drug-resistance. Drug-resistance in cancer is a difficult problem, and tackling it requires 
understanding of the broad mechanisms underlying drug-resistance and using that knowledge to 
find solutions. Although efficient treatments exist for several cancers, including CML, many lives 
are lost due to resistance. Thus, it is crucial to persist in efforts to find treatments for patients who 
are resistant to available therapies. 
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